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Riassunto 
Riassunto: Negli ultimi dieci anni è stato dimostrato come l’apolipoproteina C-III (Apo C-III), 
sulla base della forte correlazione che c’è tra i livelli plasmatici di Apo C-III e l’alta concentrazione 
sierica dei trigliceridi nell’uomo, sia un marker prognostico per il rischio cardiovascolare. A tal 
proposito la struttura molecolare dell’Apo C-III potrebbe essere rilevante. Tuttavia pochi sono gli 
studi che hanno cercato di elucidare l’impatto che la concentrazione dell’Apo C-III ed i suoi 
cambiamenti strutturali (sialilazione) hanno sul metabolismo lipidico delle lipoproteine ed inoltre 
dimostrare come l’Apo C-III possa influenzare l’andamento dei parametri associati alla patologia 
coronarica arteriosa (CAD). 
Metodi: Tre diversi gruppi di pazienti CAD, attentamente selezionati tra i soggetti arruolati nel 
progetto Verona Hearth Study, sono stati analizzati con tecnologie di proteomica e lipidomica. 
L’isoelectrofocusing e l’analisi shotgun topdown MS sono state applicate per l’identificazione e la 
quantificazione delle tre differenti glicoforme dell’Apo C-III. Il mono e bidimensionale western 
blotting sono stati utilizzati per la validazione delle proteine precedentemente identificate come 
diversamente espresse in base ai livelli di Apo C-III mediante analisi compartiva. 
Il profilo proteomico totale dei pazienti CAD è stato ottenuto tramite l’analisi SWATH, un 
approccio untargeted. L’analisi di Gas-Cromatografia e Liquid-Cromatografia-MS ha permesso la 
caratterizzazione lipidomica dei pazienti CAD e CAD free. 
Risultati: Le tre diverse glicoforme dell’Apo C-III mostrano un andamento particolare, la forma 
non sialilata presenta, infatti, un andamento negativo con gli altri parametri mentre la monosialilata 
ha un andamento positivo con tutti i parametri. Nessuna correlazione è stata osservata per la forma 
disialilata. L’analisi di validazione ha confermato i risultati dell’analisi comparativa. L’analisi 
SWATH sottolinea un particolare set di proteine associate con bassi ed alti livelli di Apo C-III. 
Mentre l’approccio lipidomico sottolinea come in base ai livelli di Apo E nei pazienti CAD e CAD 
free è possibile osservare uno specifico profilo lipidico, in particolare ad alti livelli di Apo E è 
associata la presenza di esteri del colesterolo nella forma ossidata. 
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Conclusioni: Nonostante lo studio sia stato condotto su una piccola popolazione, permette nei 
pazienti CAD attentamente selezionati una caratterizzazione del ruolo dell’Apo C-III e della 
distribuzione delle sue glicoforme. L’analisi SWATH ha rilevato un set di proteine che caratterizza 
i pazienti con alti e bassi livelli di Apo C-III. In fine l’approccio lipidomico ha sottolineato come 
nella patologia CAD un ruolo importante potrebbe essere giocato non solo dalla distribuzione delle 
apolipoproteine ed i comuni parametri lipidici osservati ma anche da peculiari specie lipidiche. 
Ulteriori analisi, con un a popolazione più grande, sono ancora richieste per validare i nostri risultati 
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Abstract 
Background: In the last decade Apolipoprotein C-III (Apo C-III) has been demonstrated to be a 
prognostic marker for cardiovascular risk on the basis of the strong correlation between Apo C-III 
plasma levels and high serum concentrations of triglyceride in humans. In such perspective, the 
molecular structure of Apo C-III may be relevant for its role  
Overall, very few studies tried to elucidate the impact of the Apo C-III concentration and 
modifications (sialylation) on lipoproteins and lipid metabolism and how Apo C-III can affect the 
outcome associated to Coronary Artery Disease (CAD) parameters. 
Methods: Three different groups of CAD patients, carefully selected among subjects enrolled in the 
Verona Heart Study project, were studied by means of proteomics and lipidomics technologies. 
Isoelectrofocusing and shotgun topdown MS approach were applied for the identification and 
quantification of the three different Apo C-III glycoforms. Mono and bidimensional western 
immunoblotting were performed in order to validate protein previously found by comparative 
analysis differentially expressed according to Apo CIII levels. A total proteomic profile of CAD 
patients was obtained by SWATH, an untargeted approach, analysis. Gas-Chromatography and 
Liquid-Chromatography-MS analysis allowed a lipidomic characterization of CAD and CAD free 
patients. 
Results: The three Apo C-III glycoforms showed a peculiar trend, where the non-sialylated form 
presented a negative correlation with the others parameters, instead the monosialylated a positive 
one. No correlations with the disialylated glycoforms were found. The validation analysis 
confirmed the comparative analysis results. The SWATH analysis underlined a peculiar set of 
proteins associated with low and high Apo C-III levels. The lipidomic approach underlined how 
according to Apo E levels in CAD and CAD free patients it is possible to observe a peculiar lipid 
profile, in particular high levels of Apo E are associated with the presence of cholesteryl ester 
oxidized. 
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Conclusion: In spite of the relatively small sample size, the study allowed a multifaceted 
characterization of Apo C-III and Apo C-III glycoforms distribution in CAD patients. SWATH 
analysis revealed a set of proteins characterizing patients with high and low levels of Apo C-III. 
The lipidomic approach underlined that not only the apolipoproteins distribution and common lipids 
parameters but also some peculiar lipid species may play an important role in CAD. To validate the 
present results, further analysis are however required, possibly on larger populations of patients . 
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Abbreviations list 
Apo A1: Apolipoprotein A1 
Apo AV: Apolipoprotein AV 
Apo B:Apolipoprotein B 
Apo C-II: Apolipoprotein II 
Apo C-III: Apolipoprotein C-III  
BHT: Butylated hydroxytoluene 
CAD: Coronary Artery Disease 
CE: Cholesteryl ester 
DDA: Data Dipendent Analysis 
DIA: Data Indipendent Analysis 
GS: Gas Chromatography 
HDL: High Density Lipoproteins 
LysoPC: Lysophosphatidylcholine 
LDL: Low Density Lipoproteins 
LPL: Lipoprotein Lipase 
LV: Latent Value 
OPLS-DA: Orthogonal Principal Component Analysis-Discriminant Analysis 
PC: Phosphatidylcholine 
PCA: Principal Component Analysis 
PLS: Partial Least Squares 
PLS-DA: Principal Component Analysis-Discriminant Analysis 
RP-LC-MS: Reverse Phase-Liquid Chromatography-Mass Spectrometry  
SWATH: Sequential Window Acquisition Of All Theoretical Fragment Ion Spectra 
TG: Triglycerides 
TAG: Triacyl Glycerole 
VHS: Verona Hearth Study 
VLDL: Very Low Density Lipoproteins 
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1.Introduction  
1.1. Coronary artery disease and risk factors 
Coronary artery disease (CAD) is multifactorial condition, involving both genetic and acquired risk 
factors in turn interacting to determine the development of the disease. Typically, coronary artery 
disease occurs when part of the smooth, elastic lining inside a coronary artery develops 
atherosclerosis.  
Atherosclerosis is a multifactorial process in whom a stringent relationship between plasma lipid 
levels and cardiovascular disease (CVD) risk has been widely recognized. (Lagrost, Gambert et al. 
1994, Berliner and Heinecke 1996, Sharrett, Ballantyne et al. 2001), 
If the crucial role of cholesterol concentrations is a long-lasting, well established notion, 
triglycerides (TG) levels and TG-rich lipoproteins have been only recently accepted and confirmed 
as an additional important risk factor for CVD (Luo and Peng 2016). A relevant support for this 
evidence, it was played by genome wide association studies (GWAS) that have identified some 
single nucleotide polymorphisms (SNPs) associated with both TG levels and CVD (Do, Willer et al. 
2013) In particular, among the candidate genes associated with TG plasma levels, recent 
observations revealed that loss-of-function (LOF) mutations in the gene encoding apolipoprotein C-
III (Apo C-III) are associated with low levels of TG, and decreased CVD risk (40–41 %) 
(Jorgensen, Frikke-Schmidt et al. 2014, Tg, Hdl Working Group of the Exome Sequencing Project 
et al. 2014) 
 
1.2. Apolipoprotein C-III 
In the last decade Apolipoprotein C-III (Apo C-III) has been demonstrated to be a prognostic 
marker of cardiovascular risk (Olivieri, Stranieri et al. 2002, Olivieri, Bassi et al. 2003, Olivieri, 
Martinelli et al. 2010). Apo C-III is a small 8.8kDa- 79 amino acids, protein, synthetized in the liver 
and in a lesser extent in the intestine; although in different proportions, it is present on the surface 
of the low density lipoprotein (LDL), very low density lipoprotein (VLDL) and high density 
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lipoproteins (HDL) (Tg, Hdl Working Group of the Exome Sequencing Project et al.). Overall, it is 
more abundant on Triglyceride-rich particles/lipoprotein (TRL) and for this reason it is considered 
mainly a marker of these lipoproteins and a primary player of their metabolism (Figure 1). In 
particular, Apo C-III affects the TRL metabolism through 3 different actions: a) by interfering with 
Apo B binding to hepatic Apo B/E receptors, as demonstrated by experiments in mouse models 
(Aalto-Setala, Fisher et al. 1992, de Silva, Lauer et al. 1994, Aalto-Setala, Weinstock et al. 1996) 
and in humans (Zheng, Khoo et al. 2007, Mendivil, Zheng et al. 2010, Zheng, Khoo et al. 2010); b) 
by inhibiting the clearance of TRL by lipoprotein lipase (LPL) in vitro (Brown and Baginsky 1972, 
Wang, McConathy et al. 1985, Yamamoto, Morita et al. 2003) and in vivo, although the finding is 
much more controversial; c) by stimulating VLDL liver secretion (Sundaram, Zhong et al. 2010, 
Yao 2012). 
 
 
Figure 1. Apo C-III effects on the lipoproteins metabolism 
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All of these findings support a strong correlation between Apo C-III plasma levels and high serum 
concentrations of TG in humans (Batal, Tremblay et al. 2000, Cohn, Patterson et al. 2004, Zheng, 
Khoo et al. 2007, Zheng, Khoo et al. 2010). 
In addition to the “lipid” effects, several pieces of evidence support a pro-inflammatory role of Apo 
C-III in atherogenetic process, i.e by stimulating monocytes adhesion to endothelial cells and by 
inducing inflammatory mediators production in these cells (Kawakami, Aikawa et al. 2006, 
Kawakami, Aikawa et al. 2006). 
 
1.3 Relation of apolipoprotein C-III, with other players: TG, PUFA, LPL, Apo AV 
Apo C-III seems to be able to delay the clearance of TRLs by inhibiting lipoprotein lipase (LPL) 
(Gangabadage, Zdunek et al. 2008, Ooi, Barrett et al. 2008). For this reason, it is a key regulator not 
only of fasting but also of postprandial TG levels (Windler and Havel 1985, Zheng, Khoo et al. 
2010). On the other hand it has been shown that polyunsaturated fatty acids (PUFA) have the ability 
to decrease the Apo C-III concentrations by means of their agonist activity on peroxisome 
proliferator receptor α (PPAR-α) (Jump, Tripathy et al. 2013), an inhibitor of APOC3 gene 
transcription (Ooi, Barrett et al. 2008). Previous in vitro study showed, in fact, evidence of an Apo 
C-III-lowering effect generally exerted by n-3 FAs (Schoonjans, Staels et al. 1996). It could be 
supposed that this Apo C-III-lowering effect could cause a consequent decrease in TG plasma levels 
avoiding the development of the atherosclerosis lesions. Nevertheless not all the patients take 
advantages by these beneficial effects of PUFAs because individuals carrying some genetic variants 
(i.e. T/C -455 on APOC3) on the promoter of APOC3 gene appear insensitive to the inhibitory 
modulation of PUFA (Olivieri, Martinelli et al. 2005).  
Another candidate gene that plays an important role in the metabolism of TG is Lipoprotein Lipase 
(LPL). LPL has both pro- and anti-atherogenic roles. The anti-atherogenic role is mostly due to the 
plasmatic LPL, whereas the pro-atherogenic role is mediated by LPL derived from vessel 
endothelial cells and macrophages (Goldberg 1996).  
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The activator apolipoprotein C-II (Apo C-II), located on the substrate lipoproteins, and 
glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1), an 
endothelial membrane protein, are needed for translocation of LPL from parenchymal cells (e.g. 
myocytes, adipocytes) where it is produced to the vascular surface of the capillary endothelium, 
where the enzyme acts (Young and Zechner 2013). Lack of any of these components results in 
severely impaired lipoprotein catabolism with massive hypertriglyceridemia (Hultin, Savonen et al. 
2013). Several other proteins influence these interactions, notably Apo C-III which inhibits and Apo 
AV which enhances lipolysis (Hultin, Savonen et al. 2013, Young and Zechner 2013). 
APOA5 gene is located closely to APOC3 gene on chromosome 11q23 in the so called “APOA1-C3-
A4 gene cluster” (Pennacchio, Olivier et al. 2001); since its discovery, apolipoprotein AV (Apo 
AV) has been recognized to be a potent factor affecting plasma TG concentrations in humans and 
mice. Apo AV is present in TG rich (chylomicrones and VLDL) and in HDL particles. In 
comparison with other apolipoproteins, Apo AV plasma concentrations in humans are very low– 
about 100 μg/l (O'Brien, Alborn et al. 2005). Others studies have shown that the binding with Apo 
AV enhances the activity of LPL (Fruchart-Najib, Bauge et al. 2004, Schaap, Rensen et al. 2004) 
and that the polymorphic variants in the APOA5 gene are associated with increased plasma TG 
levels (Pennacchio, Olivier et al. 2002, Lai, Demissie et al. 2004, Wright, Young et al. 2006, 
Grallert, Sedlmeier et al. 2007, Johansen, Wang et al. 2010, Zhao and Zhao 2010). Furthermore, 
mutations in the APOA5 gene leading to Apo AV deficiency are associated with severe 
hypertriglyceridemia in humans (Kluger, Heeren et al. 2008). APOA5 gene variants have been 
associated to insurgence of CAD and other manifestations of atherosclerosis (Hsu, Ko et al. 2006, 
Willer, Sanna et al. 2008, Laurila, Naukkarinen et al. 2010, Triglyceride Coronary Disease 
Genetics, Emerging Risk Factors et al. 2010).  
Since the identification of Apo AV as an important factor in plasma TG metabolism, three 
hypotheses explaining Apo AV action have been proposed: (1) Apo AV acts through an 
intracellular mechanism involved in VLDL synthesis and/or secretion;. (2) Apo AV accelerates the 
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hydrolysis of TRL by affecting LPL activity directly or by indirectly modifying other regulatory 
apolipoproteins of LPL, such as Apo C-III. (Atwood, Cheng et al.); 3) Apo AV acts as a ligand for 
lipoprotein receptors or proteoglycans and thereby promotes receptor-mediated endocytosis of 
lipoproteins.  
 
1.4. Apolipoprotein C-III glycoforms 
In the functional perspective above described, the molecular structure of Apo C-III may be of 
relevance. Apo C-III is present mainly in 3 isoforms termed Apo C-III0, Apo C-III1, and Apo C-
III2, depending on the number of sialic acid molecules (0 to 2) at the oligosaccharidic portions of 
the protein
 
(Nicolardi, van der Burgt et al. 2013). It has been estimated that each isoform may 
physiologically contribute, respectively, to approximately 10, 55, and 35% of the total circulating 
Apo C-III levels (Nicolardi, van der Burgt et al. 2013), but some doubts about such proportions as 
well as their relative impact on the functional activity of the TRLs still remain. In fact, overall, very 
few studies tried to elucidate the impact of the Apo C-III sialylation on lipoproteins and lipid 
metabolism. 
Results of GWAS have identified GALNT2 as a candidate gene in lipid metabolism and as a link 
between glycosylation and atherosclerosis GALNT2 codifies for N-acetylgalactosaminyltransferase 
2 (ppGalNAc-T2 ) that transfers an N-acetyl galactosamine to the hydroxyl group of a serine or 
threonine residue in the first step of O-linked oligosaccharide biosynthesis (Bennett, Weghuis et al. 
1998). The ppGalNAc-T2 belongs to a family of ppGalNAc transferases comprising 20 members in 
humans (Kosmas, Christodoulidis et al. 2014), all catalyzing the transfer of GalNAc residues onto 
proteins. 
SNPs in intron 1 of GALNT2 were found to be associated with plasma high-density lipoprotein 
cholesterol (HDL-c) and triglyceride levels (Ten Hagen, Fritz et al. 2003). A missense mutation in 
GALNT2 causing a reduction of ppGalNAc-T2 catalytic activity has been associated with reduced TG, 
increased HDL and improved postprandial TG clearance in carriers of the mutation. The data suggest that 
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this enzyme mediates these effects through glycosylation of Apo C-III, an established inhibitor of 
LPL. Since Apo C-III is a specific substrate for ppGalNAc-T2, it was studied whether sialylation of 
the sole O-linked glycan of Apo C-III might affect the enzyme affinity. It was shown that the 
neuraminidase treatment resulted in a shift from the acidic Apo C-III isoforms to Apo C-III0 due to 
the loss of sialic acids, resulting in a significant reduction of the potential of Apo C-III to inhibit 
human recombinant LPL activity (Kosmas, Christodoulidis et al. 2014). 
Thus, ppGalNAc-T2 can affect plasma lipids through posttranslational modification of Apo C-III. 
Taking into account these consideration the evaluation of the isoforms abundance could be useful to 
get new insights into the interplay between the molecules involved in the lipid metabolism and 
CAD. The process of sialylation of Apo C-III could be able to modulate VLDL and LDL particle 
size, and in turn their metabolism, leading to a longer residence time of TRL and TRL remnants in 
the circulation. Moreover, the dynamic process determining the relative amounts of Apo C-III and 
Apo E carried by TRL may be influenced by the presence of sialylated isoforms of Apo C-III, due 
to the fact that Apo C-III is generally physiologically associated with relevant amount of Apo E on 
TRL (Campos, Perlov et al. 2001, Zheng, Khoo et al. 2007, Mendivil, Zheng et al. 2010, Zheng, 
Khoo et al. 2010). In comparison to Apo C-III, Apo E plays indeed balanced and opposite roles on 
circulating LPL and with regards to its receptor ligand activity, as Apo E favors the lipolytic 
process and the clearance of TRL (Handattu, Nayyar et al. 2013, Mendivil, Rimm et al. 2013, 
White, Garber et al. 2014). Since Apo E and Apo C-III are not uniformly distributed among Apo B-
containing VLDL and LDL, the corresponding ratio with Apo B may also change according to the 
amount and characteristics of the Apo C-III isoforms present. 
 
1.4.1 Methods for Apolipoprotein C-III isoforms assay 
The first reports regarding Apo C-III isoforms were based on the use of Isoelectric focusing (IEF) 
(Catapano, Jackson et al. 1978) on the basis of the observed unsatisfactory resolution in Apo C-III 
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isoforms separation gave by polyacrylamide gel electrophoresis in either SDS or 8M urea (Kane, 
Sata et al. 1975, Carlson and Ballantyne 1976, Schonfeld, Weidman et al. 1976). 
In more recent years other researchers applied IEF for the study of Apo C-III isoforms, (Wopereis, 
Grunewald et al. 2003, Wada, Kadoya et al. 2012), connecting the IEF to immunoblotting by 
diffusion. Nevertheless, electrophoresis techniques like IEF are only semiquantitative and lack the 
capability to differentiate electrically neutral sugar moieties, electrically neutral amino acid 
substitutions, oxidation, and some others post-translation modifications (Haase, Menke-Mollers et 
al. 1988). Due to these limitations, other technologies were applied to the analysis of Apo C-III 
isoforms; in particular mass spectrometry was proven successful in identifying all the isoforms 
species (Bondarenko, Cockrill et al. 1999, Zhang, Sinaiko et al. 2012, Jian, Edom et al. 2013, 
Nicolardi, van der Burgt et al. 2013).In spite of this methodological success, the occurrence and the 
role of the different isoforms in patients or healthy subjects is still a matter of debate since not many 
studies are available so far (Yassine, Trenchevska et al. 2015, Koska, Yassine et al. 2016).  
 
1.5. Omics approaches for biomarkers identifications in cardiovascular diseases 
Omics technologies such as proteomics, matabolomics and lipidomics can be very useful for the 
discovery and measurements of biomarkers in cardiovascular diseases (Hoefer, Steffens et al. 
2015). These approaches can be directly applied to the study of existing samples collections 
(Hoefer, Steffens et al. 2015). 
 
1.5.1. Proteomics  
Proteomics has recently benefit from advances in method development, especially bioinformatics 
and instrument speed, sensitivity and resolution of mass spectrometers, for the prediction of the 
onset of CVD (Beck HC 2015). Several proteomics platforms are nowadays available and their 
selection is dependent on the type of sample and proteins to investigate (Tunon, Martin-Ventura et 
al. 2010, Langley, Dwyer et al. 2013, Hoefer, Steffens et al. 2015, Mesaros and Blair 2016). There 
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are, in general two mass spectrometry (MS) based approaches: the untargeted discovery approach 
(analysis with no a priori assumption) and the targeted MS approach (analysis of pre-selected panel 
of proteins with high precision, e.g. Multiple Reaction Monitoring). A combination of these two 
approaches is still the most comprehensive strategy for the discovery of new biomarkers by 
proteomics. In cardiovascular disease, plasma proteomics analysis has been applied for the 
discovery and measurements of new potential biomarkers (Beck HC 2015, von Zychlinski A 2015).  
  
1.6. Lipidomics and CAD 
Lipidomics or the “system-level analysis and characterization of lipids and factors that interacts 
with them” (Wenk 2005, Lisa, Cifkova et al. 2011) is an emerging area within the field of “omics” 
sciences. Lipids are involved in many cellular processes and aberrant lipid metabolism are the basis 
of some important diseases, such as diabetes, atherosclerosis, obesity, Alzheimer’s disease and 
some cancer types (Wenk 2005). This is the reason why the analysis of the lipidome and the 
complete set of lipids within a cell, tissue or organism, is of great interest. 
Among circulating metabolites in plasma, lipid molecules have a critical role in atherosclerosis and 
a profound effect on the development of cardiovascular disease (Parish, Offer et al. 2012). The 
application of lipidomic technologies to the study of cardiovascular disease will increase our 
understanding of the pathophysiological process providing a deeper insight into the patient’s 
lipidome and possibly lead to identification potential lipid biomarkers to develop new therapeutic 
strategies (Giovane, Balestrieri et al. 2008, Ekroos, Janis et al. 2010). 
Mass spectrometry (MS) is the most commonly used analytical technique in lipidomics research; 
gas chromatography mass spectrometry (GC)-MS and liquid chromatography mass 
spectrometry(LC)-MS, are mainly applied, each method having its own advantages and 
disadvantages. 
GC-MS is better for the analysis of lipids such as free fatty acids (FFAs) and steroids. Generally, 
FFAs and steroids are analyzed by transforming the compounds into volatile esters. For the analysis 
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of phospholipids, neutral lipids, and sphingolipids, which are greater in molecular weight and less 
volatile than FFAs and steroids, LC-MS is mainly used.  
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2. AIM OF THE THESIS 
As Apo C-III plays an important role in the determination of the risk of CAD in both settings of 
primary and secondary CVD prevention, this research project had, as its principal aim, the 
molecular characterization of CAD patients stratified according to Apo C-III levels.  
This characterization was obtained by the accomplishment of the following main objectives: 
 to analyze Apo C-III glycoforms initially by isoelectric focusing and subsequently by high 
resolution mass spectrometry in CAD patients stratified according to total concentration of Apo C-
III. 
 To validate by Western Immunoblotting 5 proteins (fibrinogen γ and γ’ chain, fibrinogen β, 
complement C3, serum amyloid protein) found to be modulated in CAD patients characterized by 
high and low levels of Apo C-III and PUFA  
 To study the lipoprotein lipase activity in CAD patients and correlate it with its major interacting 
factors (Apo C-III, Apo AV, etc) 
 To analyze by “bottom up approach” the plasma proteomic profiles of CAD patients stratified 
according to total concentration of Apo C-III 
  To investigate the plasma lipidomic profiles of patients (CAD and CAD free) carefully selected 
according to triglycerides, Apo C-III and Apo E levels. 
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3.Material and Methods 
3.1. Selection of patients 
We selected plasma samples of unrelated patients affected by CAD, who were previously enrolled 
in the Verona Heart Study (VHS) a cross-sectional and prospective population study with 
angiographically documented presence/absence of CAD (Olivieri, Martinelli et al. 2013). 
All the samples were collected following a standardized protocol. The plasma samples were 
prepared by collecting blood from each person after an overnight fast. Venous blood was collected 
into Vacutainer® tubes containing ethylenediaminetetraacetic acid (EDTA) and centrifuged at 2800 
g (3500 rpm) for 15 minutes at 4˚C. The plasma was separated from cellular elements (erythrocytes, 
leukocytes and platelets) and stored with protease inhibitors at -80˚C until analysis. The lipid 
distribution (total cholesterol, triglycerides, HDL, LDL) was determined on each patient’s plasma, 
according to routine standard procedures. At the time of blood sampling, a complete clinical and 
pharmacological history, including the presence or absence of cardiovascular risk factor such as 
smoking, hypertension and diabetes mellitus, was obtained from the patients. 
The study was approved by the institutional review boards of the Azienda Ospedaliera Integrata of 
Verona. Written informed consent was obtained from all the patients. 
We selected three different groups of patients belonging to the VHS population, accordingly to the 
different study aims: 
 For the analysis of the distribution of the three Apo C-III glycoforms by isoelectrofocusing 
and the validation of the differentially expressed protein by western blotting, we selected 26 
CAD patients (100% male; mean age 54.96±10.98). These patients were also subdivided in 
four groups according to total Apo C-III plasma concentration and lipid profile i.e PUFA 
plasma concentrations. 
 For the MS quantitative analysis of the three Apo C-III glycoforms and SWATH analysis 
for the total proteomic profile study, a group of 51 CAD patients (mainly males 90.2%, 
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mean age 59.6 ± 8.1 years), subdivided according to total plasma Apo C-III concentrations, 
was selected. 
 For the lipidomic analysis a group of 39 patients (17 CAD and 22 CAD free patients) 
(48.7% male, mean age 65.59±7.91), were selected. Such population was stratified 
according to Apo C-III, Apo E and TG plasma level creating six different groups of survey 
with different combinations of the three different selected parameters.  
 
3.2. Apolipoprotein assays  
Plasma concentration of total Apo C-III was determined using an automated turbidimetric 
immunoassay (Olivieri, Martinelli et al. 2010); the reagents were obtained from Kamiya (KAI-
006 (Tris buffer + goat antiserum) Seattle, WA, USA), and the procedure recommended by the 
manufacturer was implemented on an auto analyzer COBAS e501 (Roche). Imprecision was 
assessed on three pools of control sera with low, medium, and high concentrations of Apo C-III; 
intra-assay variation coefficients were 1.84%, 2.02%, and 1.98%, and inter-assay variation 
coefficients were 4.4%, 3.4%, and 2.29% for low, medium, and high concentration, respectively 
(Olivieri, Bassi et al. 2003). Based on the distribution of the apolipoprotein on the whole VHS 
population, values <9.2 mg dL
-1
 (25th percentile) and ≥ 12.6 mg dL-1 (75th percentile) were 
considered “LOW” and “HIGH” values, respectively. Briefly sample values were determined by 
interpolation of two spectrophotometric wavelengths measurements on a logit, five-points, 
calibration curve, covering the range 0.0-20.0 mg dL
-1
; for concentrations of 20-30 mg dL
-1
, a 
smaller sample volume was automatically rerun by the instrument, whereas for concentrations >30 
mg dL
-1
, the sample was manually diluted (Olivieri, Stranieri et al. 2002).  
By nephalometric assay on a nephelometer BNII Siemens (Erlangen, Germany) we also evaluated 
the Apo A-I, Apo B and Apo E plasma concentrations.  
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3.3. Fatty acids assay by gas-chromatography 
Plasmatic FA extraction and analysis 
For the fatty acids extraction 100 µl of plasma sample were added to 10 µl of internal standard 
(C:17, Sigma) to avoid the possible loss of small quantity of sample that could occur during the 
procedure making the results comparable. Three standard solution, as calibrator, were also prepared 
adding, to the 10 µl of the internal standard, 100 µl of a mix solution of known quantity of fatty 
acids. 
To each sample 2 ml of reaction solution with 1.9 ml of methanol and BHT (butyl-hydroxy-toluene 
50 mg/L, Sigma) and 100 µl of acetyl-chloride were added. After an incubation of one hour at 
100˚C, to allow the trans methylation reaction, and a cooling phase at RT, 1 ml of water and 1 ml of 
esane were added to each sample. Then the samples were vortexed and centrifuged at 2500 rpm per 
2 min. During this passage we have two phases formation, the hydrophilic one on the bottom and 
the hydrophobic one in the upper side. The supernatant was collected and underwent another step of 
fatty acids extraction through esane to collect all the traces of fatty acids present. Then the total 
solution of extraction was collected and dried at 37˚C by UniVapo (GeneVac); the dried pellet was 
solubilized in 500 µl of esane and transferred into gas-chromatography vials. 
Analyses of the plasma phospholipids fatty acids were performed on total lipids extracted using a 
gas-chromatographic method as de[Hewlett Packard 5890 chromatograph equipped with an HP-
FFAP phase column (length 25m, internal diameter 0.2 mm, phase column 0.3 µm); Hewlett 
Packard, Palo Alto, CA, USA] based on a direct fatty acid transesterification technique, as 
previously described (Olivieri, Stanzial et al. 1994). The peaks were identified and quantified by 
comparison with commercially available reference fatty acids (Sigma,St. Luis, MO, USA). Fatty 
acid C17:0 was used as the internal standard. The areas of the peaks were measured and 
subsequently quantified using a PC Vectra QS/16S equipped with HP-3365 Chem Station software 
(Hewlett Packard, Palo Alto, CA, USA) working with the operative system Microsoft Windows 3.0 
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(Malerba, Schaeffer et al. 2008). The GC analysis was obtained by applying the following 
instrument settings:  
Column: HP-INNOWax Polyethylene Glycol 30.0 m x 25 μm x 0,25 μm  
Gas carrier: Elium  
Solvent: Esane  
Oven Initial Temperature: 100 °C  
Ramp 1: 3˚C/min,  
Final temperature: 200˚C for 15 min 
Ramp 2: 3˚C/min 
Final temperature: 240˚C  
Oven final Temperature: 240 °C per 40 min  
Carrier pressure: 31,39 psi  
Column Flow: 29,4 ml/min  
Detector: FID-Flame Ionization Detector  
Hydrogen Flow to FID: 30 ml/min  
Air Flow to FID: 400 ml/min  
Temperature FID: 250 °C  
Injection Volume : 5 µl  
Injection: on-line  
Injector: split  
Split ratio: 1:10  
He Split Flow: 24,3 ml/min 
 
3.4.Apolipoprotein C-III isofocusing 
Pooled plasma samples from 4 patients belonging to the different four experimental groups, were 
analysed twice (two technical replicates) by Apo C-III isofocusing according to the method 
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described in ref. (Wopereis, Grunewald et al. 2003) with minor modification. Briefly, after a 
prefocusing step (30 min at 100V), 2 µl of sample in 20µl of IEF buffer was loaded to the gel, and 
then it was isoelectrofocused by applying 200V for 30min, 500V for 15min, 750V for 15min, and 
1000V for 75min (Wada, Kadoya et al. 2012). After IEF, gel was fixed in 12%TCA and 3.5% 
sulfosalycilic acid for 1h, then it was washed and rebalanced in transfer buffer (4M Guanidinium 
Chloride (Sigma), 0.05 M Tris-HCl (Bio-rad) pH 8, 1mg/ml DTT (Sigma)). The gel was covered 
with a nitrocellulose membrane (GE-Helthcare Amersham) and kept for 1h at 60˚C for blotting the 
proteins by diffusion. The membrane-attached gel was then soaked in 50g/l of non-fat dried milk 
dissolved in TBS containing 0.05% (v/v) Tween-20 for the removal of the membrane as well as 
blocking. The primary rabbit anti-human Apo C-III antibody (Abcam) was diluted 10000-fold, and 
the secondary goat anti-rabbit HRP-conjugated antibody (Abcam) was diluted 20000-fold in TBST. 
The proteins were detected by ECL Western blotting detection system (Euroclone). The blots were 
exposed to KODAK Biomax films (Sigma-Adrich) and the signal was quantified by densitometry 
using Quantity One image software (Bio-Rad). 
 
3.5.2D PAGE/SDS PAGE and Western immunoblotting 
2DE protein analysis was performed as previously described (Brandi, Dando et al. 2013). Briefly, 
80 µg of protein were subjected to IEF with 17 cm immobilized nonlinear pH 3–10 gradient IPG 
strips using a Protean IEF Cell (Bio-Rad). After IEF, IPG strips were equilibrated and then the 
proteins were separated using 7-20% SDS-PAGE gels. Confirmation of the proteomic data by 
immunoblot analysis was performed on an independent sample set as previously described (Polati, 
Brandi et al. 2015). In particular, 4 different samples chosen among the 4 experimental groups were 
analysed individually by 1D-WB, or as pool by 2D-WB. We investigated the modulation of 
fibrinogen , ’ and , serum amyloid component P and complement C3. Briefly, proteins separated 
by 12%T SDS-PAGE or by IEF pI 3-10, were transferred to a PVDF membrane through 
electroblotting (60 V for 2 hours at 4°C). After blocking of non-specific sites by TBST-milk 
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solution, membranes were treated with primary and secondary antibodies at the appropriate 
dilutions (see Table 1) in 1% non-fat dried milk, 0.05% Tween-20 Tris-buffered saline. The 
immunocomplexes were detected by ECL (Amersham Biosciences) by a ChemiDoc instrument 
(Bio-Rad) and the signal was quantified by densitometry using Quantity One image software (Bio-
Rad). Equal sample loading was confirmed by Amido black staining. 
 
 
Table 1. List of antibodies used for western blotting validation 
Antibody Target Western Blot Origin 
Secondary 
Antibody 
Apo C-III Apolipoprotein C-III 1:10000(IEF) Abcam Anti-Rabbit 1:20000 
Apo J Apolipoprotein J 1:1000 Santa Cruz Anti-Mouse 1:15000 
C3 Complement C3 1:1000 Santa Cruz Anti-Mouse 1:15000 
FGB Fibrinogen β (C1C3) 1:15000 GeneTex Anti-Rabbit 1:20000 
FGG Fibrinogen γ’, CT, clone 2.G2.H9 
1:1000(2D) 
1:1000(1D) 
Millopore 
Anti-Mouse 
1:15000(2D) 
1:10000(1D) 
FGG Fibrinogen γ 
1:1500(2D) 
1:5000(1D) 
GeneTex 
Anti-Rabbit 
1:20000(2D) 
1:10000(1D) 
SAP Serum Amyloid P 1:4000 GeneTex Anti-Rabbit 1:15000 
 
 
3.6.Isoforms identification and quantification by top down-shotgun mass spectrometry 
analysis 
We set up a reliable Mass Spectrometry based method to quantify Apo C-III isoforms (Apo C-III 
with 1, 2 or 0 sialic acid molecules) in a group of CAD patients, characterized by low or high levels 
of total Apo C-III plasma concentration and by low or high level of PUFA, on chronic treatment 
with statins. 
 
Sample Preparation.  
The plasma samples were processed using HybridSPE(R)-Phospolipid (Nicolardi, van der Burgt et 
al. 2013) (SUPELCO). Briefly, an aliquot of 25 μL of plasma sample was fortified with 150 μL of 
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freshly prepared 0.05% formic acid (Sigma) in water at room temperature for 15 minutes and then 
loaded onto the Solid Phase Extraction (SPE) cartridge. The SPE was preconditioned with 0.9 mL 
of 95% Acetonitrile (Sigma) and 0.05% formic acid and 0.9 mL of 0.05% tri-fluoro acetic acid 
(Sigma) in water. After loading, the SPE was washed three times with 0.9 mL of tri-fluoro acetic 
acid in water. The absorbed proteins were eluted with 200 μL of acetonitrile at 5%, 10%, 20% and 
30%. The four aliquots at 5%, 10%, 20% and 30% of acetonitrile were merged and the eluent was 
evaporated in a speedvac for further analysis (Figure 2). 
 
 
 
Figure 2. Sample preparation workflow: 200 μL of plasma sample was loaded onto an HybridSPE(R)-Phospolipid and 
the protein adsorbed were eluted with acetonitrile and undergone to top-down analysis 
 
Intact protein analysis  
The sample aliquot was used for a “top-down” analysis of Apo C-III protein and relative 
quantitation of its different glycoforms as described by Jiang et al. (Jian, Edom et al. 2013) using a 
full scan high-resolution MS approach. The sample was reconstituted with 20 μL 0.1% formic acid 
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in water and 2 μL of internal standard (IS) working solution (2.3 pg/mL of the peptide 
DPEVRPTSAVAA dissolved 0.1% formic acid in water) (Cellmano Biotech Limited). LC-MS/MS 
analyses were performed by a micro-LC Eksigent Technologies system with as stationary phase an 
Halo Fused C18 column (0.5 x 100 mm, 2.7 µm; Eksigent Technologies). The injection volume was 
4.0 µL and the oven temperature was set at 40 °C. The mobile phase was a mixture of 0.1% (v/v) 
formic acid in water (A) and 0.1% (v/v) formic acid in acetonitrile (B), eluting at a flow-rate of 15.0 
mL min
-1
 and at an increasing concentration of solvent B from 2% to 88% in 5 minutes. The LC 
system was interfaced with a 5600+ TripleTOF system (AB Sciex) equipped with DuoSpray Ion 
Source and CDS (Calibrant Delivery System). The ion source parameters in positive turbo ionspray 
mode were as follows: curtain gas 40 psi, GAS1 40 psi, GAS2 50 psi, ionspray voltage 5500 V and 
source temperature 500 °C. The declustering potential (DP) and collision energy were 165 and 10 
V, respectively. The TOF mass range was set to 600−2000 m/z, and the accumulation time was 0.25 
s. Peak integration was conducted using Skyline software. The multiple reaction monitoring 
(MRM) transitions were 1095.9 > 1095.9 (C3-0, 8+), 974.3 > 974.3 (C3-0, 9+), 1177.9 > 1177.9 
(C3-1, 8+), 1047.2 > 1047.2 (C3-1, 9+), 1214.3 > 1214.3 (C3-2, 8+), 1079.5 > 1079.5 (C3-2, 9+), 
609.8 > 609.8 (IS, 2+). 
 
Method Evaluation  
Intra-day and inter-day precision was evaluated for the glycoforms analysis. A pool of the same 
human plasma was analyzed in triplicate for three runs on separate days. The mean peak area ratios 
of Apo C-III1/Apo C-III0 and Apo C-III2/Apo C-III0 and their percentages coefficients of variation 
(% CVs) were calculated for the intra-day 3.68% and 5.95% and inter-day 5.96% and 7.52% 
analysis. The developed method is reliable and accurate upon repeated analysis as its repeatability is 
highly satisfactory for the clinical investigation. 
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3.7.Lipoprotein activity assay 
The LPL activity was measured by an LPL Activity Assay Kit (Sigma-Aldrich) on citrate plasma 
samples frozen at -80˚C until use. The evaluation of the enzymatic activity is obtained by measuring 
the fluorescence emitted by the substrate as a result of its hydrolysis by the LPL present in the 
samples analyzed. In a 96-well black plate, 100 µL of Master Reaction Mix containing 99 µL of 
LPL Assay Buffer and 0,5 µL of LPL non-fluorescent Substrate Emulsion were dispensed into each 
well (dilution 1:200). Subsequently 1 µL of sample, in 100µL of LPL Assay Buffer, were added to 
each well, to reach the total volume of 200µL. The reaction was conducted at 37˚C for 60 minutes. 
The measurement of florescence emitted from the hydrolyzed substrate was obtained by the 
microplate reader Fluoroskan (Ascent), with λ excitation = 370nm and λ emission = 450nm. The 
corrected fluorescence of the samples was obtained by subtracting the blank value. The calibration 
curve was prepared by adding 1µL of LPL Standard (represented by the hydrolyzed substrate) in 
2.5 mL of LPL Assay Buffer; serial dilutions were then prepared, each containing decreasing 
concentrations of LPL Standard, 200µL were pipetted into each well. The standard curve was 
obtained by plotting the Fluorescence Intensity Unit (FIU) as a function of μmoles of fluorescent 
substrate. The LPL activity was expressed as mol of substrate / h / ml of plasma. 
 
3.8.SWATH analysis of proteomic profile 
Sample preparation procedure 
The plasma samples were processed using the Hybrid SPE(R)-Phospolipid-RP-C4 cartridge for 
solid phase extraction. Briefly, an aliquot of 25 μL of plasma was fortified with 150 μL of freshly 
prepared 0.05% formic acid in water at room temperature for 15 minutes and then loaded onto the 
SPE. The SPE was prewashed with 0.9 mL of 95% acetonitrile/4.95% water/0.05% formic acid and 
preconditioned with 0.9 mL of 0.05% tri-fluoro acetic acid in water. After the sample loading, the 
SPE was washed three times with 0.9 mL of a tri-fluoro acetic acid solution. Plasma proteins were 
fractionated using the RP-C4 SPE: the absorbed proteins were eluted with 200 μL of acetonitrile at 
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5%, 10%, 20% and 30%. The eluted sample were merged and 250 μL of Ambic was added (pH 8.5) 
that were then digested with chymotrypsin at 1:20 (w/w) enzyme to protein ratio for 18 h at 27 °C. 
After the digestion, the sample was evaporated for the LC-MS/MS analysis (Figure 3). As Table-
isotope-labeled peptide standard (DPEVRPTSAVAA, Val- 
13
C5
15
N1 at V10, Cellmano Biotech 
Limited) was spiked into the samples before the LC-MS/MS analysis and used for instrument 
quality control. 
 
 
 
Figure 3. Sample preparation workflow: 200 μL of plasma sample was loaded onto an HybridSPE(R)-Phospolipid and 
the protein adsorbed were eluted with acetonitrile for the qualitative and quantitative proteomic profile of the sample 
 
 
Data acquisition  
The digested plasma samples were analyzed on a micro-LC Eksigent Technologies interfaced to a 
5600+ TripleTOF mass spectrometer system (AB Sciex) equipped with a DuoSpray Ion Source and 
a CDS (Calibrant Delivery System). The LC column was a Halo Fused C18 with a pre-column 
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ProteCol C18G. The mobile phase was a mixture of 0.1% (v/v) formic acid in water (A) and 0.1% 
(v/v) formic acid in acetonitrile (B), eluting at a flow-rate of 15.0 μL min−1 at an increasing 
concentration of solvent B from 2% to 86% in 17 min. The injection volume was 4.0 μL and the 
oven temperature was set at 40 °C. For identification purposes the mass spectrometer analysis was 
performed using a mass range of 100–1500 Da (TOF scan with an accumulation time of 0.25 s), 
followed by a MS/MS product ion scan from 200 to 1250 Da (accumulation time of 5.0 ms) with 
the abundance threshold set at 30 cps (35 candidate ions can be monitored during every cycle). The 
ion source parameters in electrospray positive mode were set as follows: curtain gas (N2) at 25 psig, 
nebulizer gas GAS1 at 25 psig, and GAS2 at 20 psig, ionspray floating voltage (ISFV) at 5000 V, 
source temperature at 450 C and declustering potential at 25 V. For the quantification the samples 
were subjected to cyclic data independent analysis (Stancu, Plesea et al.) of the mass spectra, using 
a 25-Da window: the mass spectrometer was operated such that a 50-ms survey scan (TOF-MS) 
was performed and subsequent MS/MS experiments were performed on all precursors. These 
MS/MS experiments were performed in a cyclic manner using an accumulation time of 40 ms per 
25-Da swath (36 swaths in total) for a total cycle time of 1.5408 s (Figure 4). The ions were 
fragmented for each MS/MS experiment in the collision cell using the rolling collision energy. The 
MS data were acquired with Analyst TF 1.7 (AB SCIEX, Concord, Canada). One data dependent 
acquisition (DDA) and three DIA acquisitions were performed. 
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Figure 4. The SWATH-MS method consists of sequential acquisition of fragment-ion spectra with overlapping 
precursor isolation windows. Here, a swath window width of 25 m/z is depicted which allows stepping through a mass 
range of 400–1200 m/z in 32 individual steps. If all fragment-ion spectra of the same isolation window are aligned, an 
MS2 map (so-called swath) is obtained (right side, swath 4 out of 32 is schematically shown). SWATH-MS data reach 
the size of terabytes. 
 
 
Protein database search 
The DDA files were searched using Protein Pilot software v. 4.2 (AB SCIEX) and Mascot v. 2.4 
(Matrix Science Inc.). The DIA files were converted to pseudo-MS/MS spectra with DIA-Umpire 
software and were searched as DDA files (Tsou, Avtonomov et al. 2015, Tsou, Tsai et al. 2016). 
Chymotrypsin as digestion enzyme was specified for both the software. For Mascot we used 2 
missed cleavages, the instrument was set to ESI-QUAD-TOF and the following modifications were 
specified for the search: carbamidomethyl cysteins as fixed modification and oxidized methionine 
as variable modification. A search tolerance of 0.08 Da was specified for the peptide mass 
tolerance, and 10 ppm for the MS/MS tolerance. The charges of the peptides to search for were set 
to 2 +, 3 + and 4 +, and the search was set on monoisotopic mass. The UniProt Swiss-Prot reviewed 
database containing human proteins (version 2015.07.07, containing 42131 sequence entries) was 
used and a target-decoy database search was performed. False Discovery Rate (FDR) was fixed at 
1%.  
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Protein quantification 
The quantification was performed by integrating the extracted ion chromatogram of all the unique 
ions for a given peptide. The quantification was carried out with PeakView 2.0 and MarkerView 
1.2. (AB SCIEX). The result file from the DDA acquisitions were used for the library generation 
using a protein FDR threshold of 1% (Wu, Song et al. 2016). Six peptides per protein and six 
transitions per peptide were extracted from the SWATH files. Shared peptides were excluded as 
well as peptides with modifications. Peptides with FDR lower than 1.0% were exported in 
MarkerView for the t-test.  
 
Multivariate Data Analysis and Model Development  
Partial Least Square (PLS) (Massart DL 1988, Vandeginste B.G.M. 1988). is a multivariate 
regression method establishing a relationship between one or more dependent variables (Y) and a 
group of descriptors (X). X and Y variables are modeled simultaneously, to find the latent variables 
(LVs) in X that will predict the LVs in Y. Here, a backward elimination (BE) strategy was also 
applied, eliminating one variable at a time, according to the minimum error in cross-validation. PLS 
was originally set up to model continuous responses but it can be applied even for classification 
purposes by establishing an appropriate Y related to the association of each sample to a class. In this 
case, where two classes are present, a binary Y variable was added, coded so that −1 is attributed to 
patients characterized by a low Apo C-III level (< 10 mg/dL) and +1 to patients characterized by 
high Apo C-III levels (> 10 mg/dL). The regression is then carried out between X-block variables 
(protein counts) and the Y just established. This application for classification purposes is called 
PLS-DA(Marengo, Robotti et al. 2008, Robotti and Marengo 2016). 
The performance of a model, and thus the ability of the significant variables to describing a defined 
group or in this case the “Apo C-III CAD state” can be evaluated analyzing the accuracy (the ratio 
of correctly assigned samples), the precision (the capability to not include samples of other classes 
in the considered class), the sensitivity (it describes the model ability to correctly recognize samples 
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belonging to the a class), the specificity (it characterizes the ability of a class to reject the samples 
of all the other classes) and the non-error-rate or NER% (is the average of the class sensitivities).  
 
3.9. Lipidomic Approach 
 Plasmatic fatty acids extraction  
To 250µl of plasma were added 2750µl of isopropanol+ BHT (butyl-hydroxy-toluene 50 mg/L) and 
vortexed. After an incubation of 1h at RT 1750µl of chloroform were added, the sample was 
vortexed and incubate at RT for 1h.the sample was then centrifuged at 3500rpm for 15 minutes. The 
supernatant was collected and dried at 37˚C by UniVapo (GeneVac); the dried pellet was 
solubilized in 500 µl of methanol and transferred into LC-chromatography MS vials. 
 
 Reverse Phase Liquid Chromatography-Electrospray Ionization- Mass Spectrometry 
Analyses (RPLC-ESI -MS) 
Liquid chromatography-electrospray ionization-mass spectrometry allows separation of a wide 
variety of intact lipid molecular species and gives detailed structural information about lipid head 
groups and the FAC regiochemical distribution (Welti, Li et al. 2002, Guella, Frassanito et al. 2003, 
Welti, Shah et al. 2007, Anesi and Guella 2015). To analyze crude lipid extracts we used a Hewlett-
Packard Model 1100 Series liquid chromatograph (Hewlett-Packard Development Company) 
coupled both to a Bruker Esquire-LC quadrupole IT-MS equipped with an ESI source (Bruker 
Optik GmbH). 
Chromatographic separation of lipids was carried out on a Kinetex-C18column (100 x 2.1 mm i.d., 
poresize100Å, particlesize 2.6 µm) (Phenomenex) with a linear gradient of solvent A 
(methanol:water 7:3, containing 12mM ammonium acetate) and solvent B (methanol containing 
12mM ammonium acetate) from 70%A/30%B to 100% B in 40 min, at a constant flow rate of 
0.3ml/min. Final conditions were kept for at least 30 min to ensure the complete elution of non-
polar lipids. Aliquots of 10 mL of crude extract in methanol. 
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Each crude extract was separately analyzed in positive ionization mode in the range 50–1200 m/z 
with a scan range of 13000 unit s
-1
. For the analysis, high purity nitrogen was used at a pressure of 
35 psi, at a temperature of 300 ˚C and a flow rate of 7 L min-1. The high voltage capillary was set at 
4000 V for positive ionization mode. 
 
Relative Quantification of Lipids and Data Analysis  
Raw data were analyzed by Data Analysis 3.0 software (Bruker Daltonik). Each lipid molecular 
species was quantified with respect to the total area of all lipid species belonging to the same class 
(e.g., relative quantification of phosphatidylcholine (PC) was performed with respect to total area of 
PC). 
For statistical analyses, the unsaturation index (UI) and the average chain length (ACL) were 
calculated for each lipid class, using the formulas  
UIclassy = Σ(relative area lipidx * double bond number of lipidx) 
and  
ACLclassy = Σ(relative area lipidx * acyl chain length of lipidx) 
where lipidx represents each single molecular species belonging to the y lipid class, respectively. 
Data were log(x+1) transformed and scaled using the Pareto method. At first, we applied a principal 
component analysis (PCA) (a unsupervised method) to define homogeneous clusters of taxa based 
on % area of single molecular species, UI and ACL. Then, we used the identified clusters as 
dependent variables first in partial least square – discriminant analysis (PLS-DA) followed by 
orthogonal partial least square (OPLS-DA), both supervised methods. Significance of PLS-DA was 
determined with permutation tests (200 permutations). PCA and DA were performed with Simca- P 
13.0 software (UmetricsAB). We furthermore analyzed the correlation loading plots of OPLS-DA 
analysis to determine which metabolites contributed to the separation of clusters by setting a 
correlation coefficient p(corr) threshold of 0.75; a two-tailed Welchtest for single candidate markers 
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was carried out to investigate their status as markers; unequal variance between groups was 
considered. 
 
3.10.Statistical Analysis 
Statistical analysis was performed with SPSS 20.0 software (IBM Corporation). Continuous 
variables are expressed as mean ± standard deviation. Statistical analysis were performed on log-
transformed values for the variables having a skewed distribution (e.g. TG, Apo E), but for sake of 
clarity they were also expressed as mean ± standard deviation. Continuous variables were analyzed 
by t-test and ANOVA, with polynomial contrasts for linear trend when indicated. Correlations 
between continuous variables were assessed by means of Pearson’s R test, as well as by linear 
regression models estimating standardized beta coefficients. Possible interactions between Apo C-
III and PUFA in determining TG plasma levels were assessed by means of general linear models. 
Categorical variables were compared using the χ2 test, with χ2 for linear trend when indicated. A P-
value <0.05 was considered significant. 
Principal Component Analysis (PCA) (Massart DL 1988, Massart DL 1998) was then applied to 
provide a general overview of the correlations existing between the variables and the existence of 
groups of samples. PCA and graphical representations were carried out by Statistica v. 7.1 (StatSoft 
Inc). PCA (Massart DL 1988, Massart DL 1998) is a multivariate pattern recognition method that 
allows the representation of the original dataset in a new reference system defined by new variables 
called principal components (PCs). PCs are linear combinations of the original variables and are 
orthogonal to each other, so that they explain independent sources of information. They are 
calculated hierarchically in order of decreasing percentage of explained variance; this feature allows 
an effective dimensionality reduction: by the use of a restricted number of significant PCs 
experimental noise and random variations, accounted for by the last PCs, can be eliminated. The 
coordinates of the samples in the space given by the PCs are called scores, while the coefficients of 
the linear combination describing each PC are called loadings and represent the weights of the 
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original variables on each PC. From the analysis of the scores it is possible to identify groups of 
samples; the reasons for their clustering can be instead identified in the corresponding loadings. 
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4. RESULTS  
4.1. Analysis of Apolipoprotein C-III glycoforms by IEF 
We selected a pool of CAD patients (n=26) subdivided according to Apo C-III and PUFA levels 
(Table 2). Briefly The samples were classified on the basis of plasmatic levels of Apo C-III as 
“low” (< 9.2 mg/dL) or “high” (≥ 12.6 mg/dL); and on the basis of fatty acids as “profile A” (> 
40% PUFA and < 25% MUFA) and “profile B” (< 40% PUFA and > 25% MUFA). As reported in 
Table 2, four groups of samples were obtained: low Apo C-III /profile A (group 1; n=7); low Apo 
C-III /profile B (group 2; n=5); high Apo C-III /profile A (group 3; n=7); high Apo C-III /profile B 
(group 4; n=7). The general characteristics of the study population are summarized in Table 3 
 
 
Table 2. Groups of CAD patients observed, subdivided according to Apo C-III levels and fatty acids profile. 
 
 
 Apo C-III plasma 
levels (mg/dl) 
MUFA (%) 
Cut off 25% 
PUFA (%) 
cut off 40% 
Group 1 (n=7) 7.19±1.71 23.27 (A) 39.25 (A) 
Group 2 (n=5) 7.25±1.35 27.18 (B) 36.54 (B) 
Group 3 (n=7) 13.78±1.53 24.20 (A) 41.52 (A) 
Group 4 (n=7) 20.83±1.73 33.12 (B) 29.98 (B) 
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Table 3. Clinical and laboratory characteristics of the considered patients. 
 
Group 1 
(n=7) 
Group 2 
(n=5) 
Group 3 
(n=7) 
Group 4 
(n=7) 
p* 
Male (%) 100 100 100 100  
Age 47.25±11.93 56±8.69 64.71±8.85 53.14±9.48 0.05 
Smoking(%) 57.14 75 57.14 83.33 <0.001 
MI (%) 0 0 0 50 <0.001 
Hypertension (%) 57.14 40 14.29 42.86 <0.001 
Diabetes (%) 0 20 0 42.86 <0.001 
Triglycerides (mmol/L) 1.22±0.44 1.19±0.62 1.49±0.68 4.21±1.81 0.01 
Total Cholesterol (mmol/L) 4.32±0.96 5.11±0.96 6.07±0.83 6.59±0.95 <0.001 
HDL-Cholesterol (mmol/L) 1.01±0.23 1.25±0.38 1.81±0.55 1.01±0.26 NS 
LDL-Cholesterol (mmol/L) 2.86±0.83 3.42±0.73 3.71±0.77 4.29±0.97 0.02 
Apo A1 (g/L) 1.15±0.16 1.21±0.20 1.64±0.39 1.25±0.16 0.02 
Apo B (g/L) 0.83±0.25 0.94±0.14 1.10±0.26 1.51±0.33 <0.001 
Apo E (g/L) 0.03±0.01 0.04±0.01 0.04±0.01 0.06±0.04 0.04 
PUFA 39.25 36.54 41.52 29.98 NS 
MUFA 23.27 27.18 24.20 33.12 NS 
NS: not significant 
 
 
To determine the frequency of different glycoforms of Apo C-III in the four analyzed groups , we 
performed a screening of pooled plasma samples by the use of IEF and subsequent immunoblotting 
(Figure 5). In all the analyzed samples it was possible to distinguish the two glycoforms of Apo C-
III (Apo C-III1, Apo C-III2); while the third glycoform (Apo C-III0) was detected albeit slightly, 
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only in the samples of group 3. The data obtained suggest that in all the CAD patients Apo C-III1 is 
more abundant than Apo C-III2 isoform.  
 
Figure 5. Apo C-III isofocusing and subsequent immunoblotting representative of the analyzed samples. Pooled plasma 
samples from patients with low Apo C-III and high PUFA (Group 1), low Apo C-III and low PUFA (Group 2), high 
Apo C-III and high PUFA (Group 3), high Apo C-III and low PUFA (Group 4), are illustrated. 
 
 
The signals obtained by technical replicates of Apo C-III isofocusing were quantified by 
densitometry using Quantity One image software (Bio-Rad). The OD of each glycoform (ODapoC3-X) 
was converted into approximate concentration (mg/dl apoC3-x) on the basis of total Apo C-III 
(mg/dl apoC3TOT) and total OD of the respective lane (ODTOT), by applying the formula: mg/dl 
apoC3-x = [ODapoC3-X * mg/dl apoC3]: ODTOT. The approximate quantification of each glycoform 
in each samples is reported in Table 4. 
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Table 4. Approximate concentration of Apo C-III glycoforms in the four groups of patients. 
 Triglycerides 
mmol/l 
Apo C-III 0 
mg/dl 
Apo C-III 1 
mg/dl 
Apo C-III 2 
mg/dl 
Group 1 1.16  4.9 ± 1.0 3.4 ± 1.3 
Group 2 1.06  3.3 ± 1.1 3.6 ± 0.8 
Group 3 1.48 1.7 ± 1.1 6.8 ± 0.7 7.4 ± 1.1 
Group 4 4.21  12.9 ± 1.2 8.4 ± 1.8 
 
 
4.2. Proteomic analysis of CAD patients stratified according to different levels of Apo 
C-III and fatty acids 
Previous comparative proteomic analysis results underlined a total of 43 differentially expressed 
proteins which are mainly involved in coagulation, complement activation, inflammatory immune 
response and lipid metabolism. This is the reason why we have decided to investigate, through 
western immunoblotting, in our four groups of survey, how the Apo C-III can affect the expression 
of a selected group of protein. 
 
Western blot validation of deregulated protein species  
We measured the level of Serum Amyloid Protein Complement C3, Fibrinogen γ, Fibrinogen γ’ and 
Fibrinogen β by Western Blotting (Do, Willer et al.) using samples belonging to the four groups 
(Table 2). The 1D (Figure. 6) and 2D-WB (Figure. 7) confirmed the proteomics findings and 
suggested a trend of up-regulation of fibrinogen  in the comparison between group 1 vs group 2, as 
well as, in the comparison between samples with high Apo C-III (groups 3+4) and with low Apo C-
III (groups 1+2). The 2D immunodetected profiles confirmed a strong up-regulation of complement 
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C3 in the comparison between group 1 vs group 2. As concerning the fibrinogen , the data 
obtained confirmed the down-regulation of this protein in the comparison between group 3 and 
group 4; and also in samples with high Apo C-III (groups 3+4) as compared to samples with low 
Apo C-III (groups 1+2). Unfortunately, the 2D immunodetected profiles do not allowed to confirm 
lower amount of serum amyloid component P in plasma samples with high Apo C-III (i.e groups 3 
and 4). It should however be noted that 2D-WB suggest a prevalence of serum amyloid in the 
groups 1 and 3, that are characterized by a greater presence of PUFAs (Figure 7). 
 
 
 
Figure 6. Monodimensional western blot analysis of fibrinogen ’ and  in plasma samples belonging to the four groups 
of CAD patients. Amido black was used as loading control.  
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Figure 7. 2D western blot analysis of serum amyloid protein, fibrinogen  , ’,  and complement C3 in plasma samples 
belonging to the four groups of CAD patients. Amido black was used as a loading control. 
 
 
4.3. Glicoforms quantification in CAD patients by Shotgun-Topdown MS analysis 
After the first analysis of Apo C-III isoforms by IEF as illustrated in the previous paragraphs we 
moved to a more powerful methodology. We in fact applied high resolution mass spectrometry to 
the analysis of Apo C-III glycoforms in a different set of plasma samples. By applying this 
technology we were able to detect and quantify Apo C-III non sialylated (Apo C-III0), 
monosialylated (Apo C-III1)and disialylated (Apo C-III2) . 
 
Apolipoprotein C-III plasma concentration and glycoforms: relationship with 
traditional plasma lipid profile and apolipoproteins 
The general characteristics of the 51 patients study population are summarized in Table 5. Plasma 
lipids parameters, as well as demographic data, are shown in Table 6 stratified on the basis of 
quartile distribution of Apo C-III plasma concentration. As expected, subjects within the highest 
Apo C-III quartile were characterized by an unfavorable lipid profile with higher levels of 
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triglycerides, total and LDL cholesterol, as well as higher Apo B and Apo E plasma concentrations. 
Such results were confirmed by Pearson’s correlation analysis (Table 7). Considering the relative 
proportion of Apo C-III glycoforms, heterogeneous trends of correlations were observed (Table 7).  
Apo C-III0 had an inverse correlation (R= -0.351; P=0.009), Apo C-III1 a direct correlation 
(R=0.382; P=0.004), while Apo C-III2 did not have any significant correlation with total Apo C-III 
plasma concentrations, as shown in the scatter plot (Figure 8) and in the histogram depiction 
(Figure 9). 
 
 
Table 5. Clinical and laboratory characteristics of the cohort of patients with coronary artery disease(CAD) 
 CAD patients (n=51) 
Age (years) 59.6±8.1 
Male sex (%) 90.2 
Myocardial infarction history (%) 56.9 
Smoking history (%) 72.5 
Hypertension (%) 68.6 
Diabetes (%) 15.7 
Total cholesterol (mM/L) 4.41±0.81 
LDL  cholesterol (mM/L) 2.94±0.75 
HDL  cholesterol (mM/L) 1.10±0.28 
Triglyceride (mM/L) 1.87±0.96 
Apolipoprotein A (g/L) 1.48±0.21 
Apolipoprotein B (g/L) 0.78±0.24 
Apolipoprotein E (g/L) 0.039±0.014 
Apolipoprotein C-III (mg/dl) 10.21±1.01 
Lipoprotein Lipase activity 1.56±0.59 
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Table 6. Plasma lipid profile parameters according to apolipoprotein C-III (Apo C-III) quartiles distribution. 
 Apo C-III quartiles  
 <8.7 
(mg/dl) 
8.7-11.6 
(mg/dl) 
11.7-13.8 
(mg/dl) 
>13.8 
(mg/dl) 
P* 
Age (years) 60.6±7.7 57.9±8.0 62.0±4.1 58.1±10.9 NS 
Male sex (%) 100 92.3 91.7 76.9 NS 
Chol tot (mM/L) 3.90±0.36 4.20±0.46 4.56±0.84 5.00±1.02 <0.001 
LDL (mM/L) 2.55±0.31 2.75±0.48 3.08±0.81 3.40±0.97 0.001 
HDL (mM/L) 1.15±0.27 1.11±0.31 1.07±0.28 1.05±0.27 NS 
TG (mM/L) 1.01±0.25 1.64±0.76 2.10±0.58 2.73±1.08 <0.001 
Apo A (g/L) 1.41±0.23 1.47±0.16 1.51±0.24 1.52±0.19 NS 
Apo B (g/L) 0.64±0.13 0.73±0.15 0.79±0.29 0.95±0.27 0.001 
Apo E (g/L) 0.032±0.010 0.036±0.012 0.038±0.009 0.052±0.017 <0.001 
Apo C-III (mg/dl) 6.88±1.56 10.21±1.01 12.88±0.57 16.60±1.96 <0.001 
LPL activity (mol/h/ml) 1.84±0.59 1.62±0.66 1.48±0.59 1.36±0.46 0.035 
* by ANOVA with polynomial contrasts for linear trend or by 2-test for linear trend. 
NS: no significant 
 
41 
Table 7. Correlations of apolipoprotein C-III total plasma concentration and glycoforms proportion with traditional 
plasma lipid profile. 
  Apo C-III Chol HDL LDL TG Apo A Apo B Apo E 
T
o
ta
l 
p
la
sm
a
 
c
o
n
ce
n
tr
a
ti
o
n
 Apo C-III - r= 0.618 
p< 0.001 
r=-0.153 
p=0.280 
r= 0.545 
p= 0.001 
r= 0.720 
p< 0.001 
r= 0.111 
p= 0.437 
r=0.601 
p< 0.001 
r=0.536 
p<0.001 
G
ly
co
fo
rm
s 
p
ro
p
o
rt
io
n
 
Apo C-III0 r= -0.343 
p= 0.014 
r= -0.304 
p= 0.030 
r= 0.224 
p= 0.114 
r= -0.314 
p= 0.025 
r= -0.390 
p= 0.005 
r= 0.222 
p= 0.117 
r= -0.299 
p= 0.033 
r= -0.370 
p= 0.007 
Apo C-III1 r= 0.395 
p= 0.004 
r= 0.330 
p= 0.018 
r= -0.356 
p= 0.010 
r= 0.388 
p= 0.005 
r= 0.398 
p= 0.004 
r=-0.137 
p= 0.337 
r= 0.334 
p= 0.017 
r= 0.395 
p< 0.004 
Apo C-III2 r= -0.126 
p= 0.380 
r= -0.086 
p= 0.548 
r= 0.202 
p= 0.154 
r= -0.148 
p= 0.299 
r= -0.080 
p= 0.576 
r= 0.064 
p= 0.655 
r=-0.097 
p= 0.499 
r= -0.097 
p= 0.500 
ApoC-III1/ApoC-III0 
Ratio 
r= 0.431 
p= 0.002 
r= 0.382 
p= 0.006 
r= -0.305 
p= 0.030 
r= 0.416 
p= 0.002 
r= 0.440 
p= 0.001 
r= -0.165 
p= 0.247 
r= 0.376 
p= 0.007 
r= 0.431 
p= 0.002 
Significant correlations are reported in bold type 
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Figure 8. Scatter plot of correlations between apolipoprotein C-III glycoforms and apolipoprotein C-III total plasma 
concentration. 
 
 
 
Figure 9. Apolipoprotein C-III glycoforms distribution according to total plasma Apolipoprotein C-III concentration 
stratification in quartiles. 
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The Apo C-III glycoforms, considered as relative proportion, showed different correlations with the 
other plasma lipids parameters (Table 7). Apo C-III0 was inversely correlated with total and LDL 
cholesterol, TG, Apo B, and Apo E. In contrast, Apo C-III1 was directly correlated with total and 
LDL cholesterol, TG, Apo B, Apo E, and inversely with Apo A. No significant correlation was 
found for Apo C-III2. On the basis of such observations, to enhance the statistical associations 
related to Apo C-III glycoforms, the ratio of Apo C-III1 on Apo C-III0 (Apo C-III1/Apo C-III0) 
was also calculated. Apo C-III1/Apo C-III0 correlated directly with total and LDL cholesterol, TG, 
Apo B, Apo C-III, Apo E, and inversely with HDL, thus reflecting an unfavorable lipid profile 
(Table 7). Most of these correlations were no more statistical significant after adjustment for total Apo C-III 
concentrations, with the exception of that with TG. Apo C-III1/Apo C-III0 remained a significant predictor 
of TG levels (standardized β coefficient=0.205; P=0.028) in a linear regression model adjusted for sex, age, 
and total Apo C-III concentrations, while the association with Apo E was of borderline significance 
(standardized β coefficient=0.252; P=0.059 by adjusted linear regression model). 
 
Apo C-III plasma concentration and glycoforms: relationships with plasma fatty acids 
Plasma fatty acid data are summarized in Table 8. Analyzing the possible correlations between Apo 
C-III (considered both as total plasma concentration and as proportion of glycoforms) and plasma 
fatty acid profile (expressed as relative percentage), several significant associations were found by 
Pearson’s test (Table 9). Total Apo C-III plasma concentration correlated directly with C14:0, 
MUFA, C16:1, and inversely with C20:0, PUFA, C18:4ω3, PUFA ω6, C18:2ω6. Apo C-III0 
correlated directly with C20:0, C24:0, C26:0, C20:4ω6 and inversely with C14:0. Apo C-III1 
correlated directly with C14:0 and inversely with C20:0. Apo C-III2 correlated inversely with 
C26:0, C18:3ω3, and C20:4ω6. Apo C-III1/Apo C-III0 correlated directly with C14:0 and inversely 
with C20:0 and C24:0 (Table 9). Including all the significant correlations in adjusted linear 
regression models C20:0, C18:4ω3, and C18:2ω6 remained significant predictors of Apo C-III 
plasma concentration variability, C14:0 and C26:0 of Apo C-III0 variability, C14:0 of Apo C-III1 
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variability, C18:4ω3 of Apo C-III2 variability, C14:0 and C20:0 of Apo C-III1/Apo C-III0 ratio 
(Table 10). These results were confirmed also by principal component analysis (PCA) (Figure 10). 
 
Table 8. Plasma Fatty Acids levels in the cohort of patients with coronary artery disease (CAD). 
 CAD patients 
SFA (g/100g) 31.3±1.8 
 C14:0 1.3±0.422 
 C16:0 21.1±1.4 
 C18:0 7.3±0.7 
 C20:0 0.3±0.05 
 C22:0 0.6±0.14 
 C24:0 0.44±0.1 
 C26:0 0.11±0.05 
MUFA (g/100g) 29.5±3.3 
 C16:1 1.96±0.8 
 C18:1 27.3±3.1 
 C20:1 0.2±0.05 
PUFA (g/100g) 39.2±3.8 
 ω3PUFA (g/100g) 3.12±0.8 
 C18:3ω3 0.35±0.2 
 C18:4ω3 0.15±0.07 
 C20:5ω3 0.65±0.4 
 C22:6ω3 1.97±0.6 
 ω6PUFA (g/100g) 36.1±3.8 
 C18:2ω6 26.4±3.9 
 C20:2ω6 0.3±0.6 
 C20:4ω6 9.42±1.7 
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Table 9. Correlations of Apo C-III total plasma concentration and glycoforms proportions with fatty acids plasma levels. 
 
 SFA C14:0 C16:0 C18:0 C20:0 C:22 C24:0 C26:0 MUFA C16:1 C18:1 C20:1 
Apo C-III tot 
r= 0.196 
p= 0.152 
r= 0.405 
p= 0.002 
r= 0.183 
p= 0.182 
r= 0.007 
p= 0.957 
r= -0.518 
p< 0.001 
r=-0.228 
p= 0.095 
r= -0.294 
p= 0.029 
r=-0.160 
p= 0.245 
r= 0.507 
p< 0.001 
r= 0.467 
p< 0.001 
r= 0.434 
p= 0.001 
r= 0.207 
p= 0.130 
Apo C-III0 
r= -0.036 
p= 0.796 
r= -0.274 
p= 0.043 
r= -0.057 
p= 0.678 
r= 0.075 
p= 0.584 
r= 0.293 
p= 0.030 
r= 0.218 
p= 0.110 
r= 0.332 
p= 0.013 
r= 0.411 
p= 0.002 
r= -0.256 
p= 0.059 
r= -0.192 
p= 0.159 
r= -0.230 
p= 0.091 
r= -0.033 
p= 0.811 
Apo C-III1 
r= 0.246 
p= 0.070 
r= 0.396 
p= 0.003 
r= 0.189 
p= 0.167 
r= 0.059 
p= 0.670 
r= -0.328 
p= 0.014 
r=-0.143 
p= 0.296 
r= -0.196 
p= 0.151 
r=-0.060 
p= 0.662 
r= 0.119 
p= 0.387 
r= 0.163 
p= 0.234 
r= 0.089 
p= 0.517 
r= 0.021 
p= 0.878 
Apo C-III2 
r= -0.254 
p= 0.061 
r= -0.187 
p= 0.172 
r= -0.165 
p= 0.230 
r= -0.147 
p= 0.285 
r= 0.088 
p= 0.524 
r=-0.054 
p= 0.697 
r= -0.108 
p= 0.432 
r=-0.349 
p= 0.009 
r= 0.122 
p= 0.376 
r= 0.005 
p= 0.974 
r= 0.130 
p= 0.343 
r= 0.009 
p= 0.950 
Apo C-III1/Apo C-III0 
Ratio 
r= 0.173 
p= 0.207 
r= 0.376 
p= 0.005 
r= 0.151 
p= 0.273 
r= -0.003 
p= 0.982 
r= -0.399 
p= 0.011 
r=-0.187 
p= 0.172 
r= -0.286 
p= 0.035 
r=-0.239 
p= 0.079 
r= 0.201 
p= 0.140 
r= 0.203 
p= 0.137 
r= 0.169 
p= 0.217 
r= 0.016 
p= 0.906 
 
 PUFA PUFAω3 C18:3ω3 C18:4ω3 C20:5ω3 C22:6ω3 PUFAω6 C18:2ω6 C20:2ω6 C20:4ω6 
Apo C-III tot 
r= -0.530 
p< 0.001 
r= 0.015 
p= 0.915 
r= 0.071 
p= 0.608 
r= -0.269 
p= 0.047 
r= 0.068 
p= 0.624 
r= -0.116 
p= 0.401 
r= -0.522 
p< 0.001 
r= -0.501 
p< 0.001 
r= 0.016 
p= 0.908 
r= -0.018 
p= 0.896 
Apo C-III0 
r= 0.239 
p= 0.079 
r= 0.144 
p= 0.294 
r= -0.141 
p= 0.305 
r= 0.232 
p= 0.088 
r= 0.258 
p= 0.059 
r= 0.131 
p= 0.339 
r= 0.203 
p= 0.136 
r= 0.067 
p= 0.628 
r= 0.060 
p= 0.667 
r= 0.308 
p= 0.022 
Apo C-III1 
r= -0.216 
p= 0.113 
r= -0.135 
p= 0.326 
r= 0.107 
p= 0.438 
r= 0.093 
p= 0.498 
r= -0.183 
p= 0.186 
r= -0.168 
p= 0.221 
r= -0.182 
p= 0.184 
r= -0.168 
p= 0.221 
r= 0.064 
p= 0.648 
r= -0.033 
p= 0.813 
Apo C-III2 
r= 0.011 
p= 0.936 
r= 0.012 
p= 0.933 
r= 0.018 
p= 0.896 
r= -0.348 
p= 0.009 
r= -0.048 
p= 0.730 
r= 0.063 
p= 0.646 
r= 0.006 
p= 0.964 
r= 0.129 
p= 0.346 
r= -0.132 
p= 0.345 
r= -0.277 
p= 0.041 
Apo C-III1/Apo C-III0 
Ratio 
r= -0.254 
p= 0.061 
r= -0.134 
p= 0.329 
r= 0.129 
p= 0.349 
r= -0.069 
p= 0.615 
r= -0.216 
p= 0.117 
r= -0.150 
p= 0.275 
r= -0.220 
p= 0.106 
r= -0.139 
p= 0.313 
r= -0.002 
p= 0.990 
r= -0.182 
p= 0.184 
Significant correlations are reported in bold type 
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Table 10. Fatty acid plasma levels as determinants of Apo C-III plasma concentration (A) and glycoforms proportion 
(B.C.D.E) 
A) Apo C-III plasma concentration 
 Standardized β-coefficient P 
C20:0 -0.420 <0.001 
C18:4 ω-3 -0.275 0.007 
C18:2 ω-6 -0.449 <0.001 
R2=  0.516 
B) Apo C-III 0 glycoform proportion 
 Standardized β-coefficient P 
C14:0 -0.250 0.046 
C26:0 0.395 0.002 
R2= 0.231  
C) Apo C-III 1 glycoform proportion 
 Standardized β-coefficient P 
C14:0 0.396 0.003 
R2= 0.157 
D) Apo C-IIApo C-III 2 glycoform proportion 
 Standardized β-coefficient P 
C26:0 -0.241 0.063 
C18:4 ω-3 -0.290 0.024 
C20:4 ω-6 -0.236 0.060 
R2= 0.250 
E) Apo C-III 1 / Apo C-III 0 ratio 
 Standardized β-coefficient P 
C14:0 0.289 0.037 
C20:0 -0.230 0.094 
R2= 0.187 
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Figure 10. PCA results: score plot of the first two PCs on Apo C-III glycoforms, Apo C-III1/Apo C-III1 ratio and Fatty 
Acids 
 
 
Interaction between Apo C-III and PUFA in determining TG levels. 
As expected by earlier studies (Mensink, Zock et al. 2003, Bays, Tighe et al. 2008, Furtado, 
Campos et al. 2008) the results showed an inverse correlation of PUFA with TRL-related 
parameters, i.e. TG (R= -0.572; P<0.001) and Apo C-III (R= -0.521; P<0.001). We hypothesized 
that such associations could be influenced by Apo C-III levels and performed a new analysis 
stratifying the study population on the basis of Apo C-III median value (11.7 mg/dl). In subject with 
low Apo C-III plasma concentration (<11.7 mg/dl), PUFA correlated inversely with TG and Apo C-
III, as well as there was a positive correlation with Apo C-III0 and negative correlations with Apo 
C-III1 and Apo C-III1/Apo C-III0 (Table 11A). In contrast, for the group of subjects with high Apo 
C-III plasma concentration (≥11.7 mg/dl), no significant correlation was found (Table 11B). There 
was a significant interaction between Apo C-III and PUFA levels in determining TG plasma 
concentration (F=5.483; P for interaction=0.023 by general linear model – Figure 11). 
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Table 11. Correlations of PUFA levels with triglyceride and apolipoprotein C-III plasma concentration and glycoforms 
stratified according apolipoprotein C-III plasma concentration median value (11.7mg/dl) 
A) Apo C-III< 11.7mg/dl  
 TG Apo C-III tot Apo C-III0 Apo C-III1 Apo C-III2 Apo C-III1/ 
ApoC-III0 
PUFA r= -0.568 
p= 0.001 
r= -0.374 
p= 0.046 
r=0.390 
p= 0.037 
r= -0.403 
p= 0.030 
r= -0.004 
p= 0.982 
r= -0.453 
p= 0.014
 
B) Apo C-III≥11.7mg/dl 
 TG Apo C-III tot Apo C-III0 Apo C-III1 Apo C-III2 Apo C-III1/ 
ApoC-III0 
PUFA r= 0.037 
p= 0.858 
r= 0.091 
p= 0.658 
r=-0.122 
p= 0.554 
r= 0.196 
p= 0.337 
r=-0.116 
p= 0.571 
r= 0.169 
p= 0.409 
 
Significant correlations are reported in bold type 
 
 
Figure 11. Interaction between Apo C-III and PUFA levels in determining TG plasma concentration. The study 
population was subdivided according to Apolipoprotein C-III plasma median value (11.7 mg/dl). 
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Apolipoprotein C-III plasma levels correlation with fibrinogen chains plasma 
concentration 
On the basis of the validation results obtained in the previously analyzed cohort we further 
focalized our attention on fibrinogen γ’ chain, because several studies show that this isoform levels 
increased in CAD patients (Lovely, Falls et al. 2002, Lovely, Kazmierczak et al. 2010).This isoform 
has also thrombogenic effects in arterial site and anti-thrombogenic effect in venous site (Uitte de 
Willige, de Visser et al. 2005, Lovely, Boshkov et al. 2007). It could be supposed that these latter 
functions of Fibrinogen γ’ could be associated with Apo C-III levels so we analyzed the trend of 
Fibrinogen γ’chain in the same 51 CAD patients population of MS analysis (Figure 12) to found 
any possible correlation between Apo C-III and Fibrinogen γ’ levels. 
The analysis between Fibrinogen γ, Fibrinogen γ’ and Fibrinogen γ/Fibrinogen γ’ ratio and all the 
lipid profile data didn’t show any statistically significant correlation with Apo C-III levels, but a 
statististically significant correlation with LDL and Apo B levels (p<0,05 for both analyses) was 
found.  
 
 
 
Figure 12. Western blots analysis representative of the  data obtained with antibodies against fibrinogen gamma and 
gamma’ chain in the selected CAD patients. 
 
 
4.4. Lipoprotein lipase analysis 
An endpoint analysis was performed in order to assess the LPL activity and analyze it according to 
both total plasma concentration of Apo C-III and Apo C-III glycoforms.  
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Evaluation of LPL activity on the 51 CAD patient, previously analyzed for the quantification of 
Apo C-III glycoforms by topdown analysis, was performed by mean of fluorescence assay. A 
standard curve was obtained and used for the extrapolation of the enzymatic activity (Figure 13). 
 
 
 
Figure 13. LPL assay standard curve. 
 
 
After statistical evaluation of the results we observed that, as expected, LPL activity decreased 
progressively across Apo C-III quartiles, from the lowest to the highest (Figure 14). On the other 
hand, no association was found between LPL activity and the relative proportion of Apo C-III 
glycoforms (Table 12). Considering the absolute plasma concentration of Apo C-III glycoforms, all 
the three isoforms have a similar trend of association with LPL activity with a progressive decrease 
of enzyme activity from the lowest to the highest plasma concentration (Figure 15) 
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Figure 14. Distribution of LPL activity according to total plasma Apolipoprotein C-III concentration stratification in 
quartiles. 
 
 
Table 12. LPL activity correlation with Apo C-III glycoforms 
 Apo C-III0 Apo C-III1 Apo C-III2 
LPL activity 
r= 0.022 
p= 0.880 
r= -0.052 
p= 0.723 
r= 0.040 
p= 0.782 
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Figure 15. Association between LPL activity and Apo C-III glycoforms distribution according to total plasma 
Apolipoprotein C-III concentration stratification in quartiles: A) Apo C-III0; B)Apo C-III1; C)Apo C-III2. 
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4.5. Plasma Proteome profiles of CAD patients 
The plasma proteomic profile of the same set of 51 CAD patients with high and low total Apo C-III 
was obtained using shotgun LC-MS analysis. The LC-MS analysis allowed the identification of 289 
proteins, 180 of them were quantified. Figure 16 shows the histogram of the log 10 Fold-Change 
(FC) of the CAD plasma samples divided into two classes: Apo C-III > 10 mg/dL Vs Apo C-III < 
10 mg/dL. The up and down regulated proteins were selected using p value <0.05 and fold change 
>1.3. A total of 21 proteins were regulated, including 7 upregulated and 4 downregulated with FC 
≥1.5 (see Table 13) 
 
 
 
Figure 16. log 10 fold-Change of the CAD plasma samples: CAD patients with Apo C-III >10 mg/dL and with Apo C-
III < 10 mg/dL were employed (high Apo C-III vs low Apo C-III). 
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Table 13. Proteins names, protein accession number, fold change, gene, biological process and molecular function 
classifications of modulated proteins in CAD patients (protein associated with high Apo C-III levels (Apo C-III> 10: 
FC>1.5). 
Protein names 
Protein  
accession 
FC up 
vs down 
Gene 
GO biological 
process 
GO molecular function 
Keratin, type II cytoskeletal 
6A 
K2C6A_HUMAN 4.76 KRT6A 
Cell growth 
and/or 
maintenance 
Structural constituent of 
cytoskeleton 
Ig lambda-7 chain C region LAC7_HUMAN 2.12 IGLL5 
Complement 
activation 
Serine-type endopeptidase 
activity 
RPA-interacting protein 
(hRIP) 
RIP_HUMAN 1.96 RPAIN DNA repair Protein complex binding 
Complement C2 CO2_HUMAN 1.93 C2 
Complement 
activation 
Serine-type endopeptidase 
activity 
Keratin, type I cytoskeletal 
9 
K1C9_HUMAN 1.70 KRT9 
Cell growth 
and/or 
maintenance 
Structural constituent of 
cytoskeleton 
Apolipoprotein C-II APOC2_HUMAN 1.59 APOC2 
Lipoprotein 
metabolic process 
Lipid binding 
Protein AMBP AMBP_HUMAN 1.45 AMBP Immune response 
Serine-type endopeptidase 
inhibitor activity 
Retinol-binding protein 4 RET4_HUMAN 1.41 RBP4 
Cardiac muscle 
tissue 
development 
Transporter activity 
Vitronectin (VN) VTNC_HUMAN 1.36 VTN 
Immune response 
negative 
regulation of 
blood coagulation 
Extracellular matrix binding 
Complement C1q 
subcomponent subunit C 
C1QC_HUMAN 1.35 C1QC 
Complement 
activation 
Serine-type endopeptidase 
activity 
Apolipoprotein E APOE_HUMAN 1.33 APOE 
Lipoprotein 
metabolic process 
negative 
regulation of 
blood coagulation 
Low-density lipoprotein 
particle receptor binding 
Piezo-type 
mechanosensitive ion 
channel component 2 
PIEZ2_HUMAN 0.75 PIEZO2 Cation transport 
Mechanically-gated ion 
channel activit 
Immunoglobulin heavy 
variable 3-13 
HV305_HUMAN 0.75 IGHV3-13 
Complement 
activation 
Serine-type endopeptidase 
activity 
Alpha-1-antitrypsin A1AT_HUMAN 0.74 SERPINA1 
Acute-phase 
response 
blood coagulation 
Serine-type endopeptidase 
inhibitor activity 
Immunoglobulin heavy 
variable 3-23 
HV303_HUMAN 0.73 IGHV3-23 
Complement 
activation 
Serine-type endopeptidase 
activity 
CD5 antigen-like CD5L_HUMAN 0.71 CD5L Immune response 
Defense/immunity protein 
activity 
Ig mu chain C region IGHM_HUMAN 0.59 IGHM Immune response Antigen binding 
Ig mu heavy chain disease 
protein (BOT) 
MUCB_HUMAN 0.50 
 
Immune response Antigen binding 
Serum amyloid A-1 protein SAA1_HUMAN 0.36 SAA1 
Innate immune 
response 
Antigen binding 
Putative methyltransferase 
NSUN3 
NSUN3_HUMA
N 
0.16 NSUN3 rRNA methylation Methyltransferase activity 
 
 
The 21 regulated proteins were, then, submitted to the web-based tool Cytoscape to visualize the 
non-redundant GO terms and pathways in functionally organized networks: the resulted image 
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(Figure 17) reflects the relations between the biological terms based on the similarity of their linked 
gene/proteins. The analysis revealed the presence of four functional clusters linked to the 
complement activation, the low-density lipoprotein, the acute phase response and the intermediated 
filament based process 
The Cytoscape environment was subdivided in two protein groups (up-regulated and down-
regulated) that were used in order to illustrate their functional differences, as reported in Figure 17. 
Figure 17 shows a clear up regulation of lipoprotein metabolism protein (up-regulated in patients 
with high Apo C-III), the proteins linked to the activity of the complement are both up and down 
regulated, while the acute phase response group is down-regulated. 
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Figure 17. Cytoscape representation of functional clusters of regulated proteins in patients with high Apo C-III levels. 
Lipoprotein metabolism proteins are up-regulated, the proteins linked to the activity of the complement are both up and 
down regulated, while the acute phase response group is down-regulated 
 
 
A protein-protein interaction analysis of the significant proteins was performed using STRING 
(Search Tool for the Retrieval of Interacting Genes) (Figure 18). STRING is a freely available 
database that relies on known and predicted protein interactions and that quantitatively integrates 
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interaction data from high-throughput experiments, genomic context, co-expression and other 
literature. 
 
Figure 18. STRING network analysis of up regulated and down regulated proteins for the CAD patients with high Apo 
C-III levels. 
 
 
The network related to lipoprotein metabolism, already highlighted by Cytoscape, shows that 
APOC3 and APOC2 have a co-expression connection while APOC3 - APOE and APOC2 - APOE 
are characterized by an interaction linked to literature works.  
 
 
Multivariate statistical analysis 
In the case where a large number of descriptors (X variables) are present or a large experimental 
error is expected, it can be quite difficult to obtain a final model described by representative 
variables with a suitable predictive ability. In these cases, techniques for variable selection such as 
partial least square – discriminant analysis (PLS-DA) are usually exploited. 
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The PLS-DA was performed on all the samples in order to identify clusters and protein correlations 
between the two groups of CAD patients. The dataset was arranged in a matrix of 153 samples (51 
patients x 3 instrumental replications, divided in two groups: patients with Apo C-III plasma levels 
< 10 mg/dL and  patients with Apo C-III plasma levels > 10 mg/dL) and 180 variables (the signal of 
the quantified proteins). Data were first row-scaled to eliminate variations due to small differences 
in the total protein content of the initial sample; then, autoscaling was applied by the following 
equation: 
𝑥′𝑖𝑗 =
(𝑥𝑖𝑗 − ?̅?𝑗)
𝑠𝑗
 
where 𝑥′𝑖𝑗 is the autoscaled value for the i-th sample and the j-th variable, 𝑥𝑖𝑗  is the row-scaled 
value for the i-th sample and the j-th variable and 𝑠𝑗 is the standard deviation of the j-th variable 
after row-scaling. 
After autoscaling all the variables are characterized by a null average value and unit variance, so 
that scale effects are eliminated. PLS-DA was then applied with a variable selection procedure in 
backward elimination: one variable is eliminated at a time according to the lowest error in cross-
validation. Leave-more-out cross-validation was applied with 5 cancellation groups, taking out all 
the three replications of the same sample at a time. The final model contains 42 proteins and 3 latent 
variables (LVs). 
We then performed the partial least square – discriminant analysis (PLS-DA) on all the samples in 
order to identify clusters and protein correlations between the two groups of CAD patients: Apo C-
III < 10 mg/dL (blue dot) and Apo C-III > 10 mg/dL (red dot) (Figure 19). The PLS-DA model was 
carried out in a variable selection with backward elimination in cross-validation. 
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Figure 19. Score plot of the first three LVs calculated. Samples are separated according to the corresponding plasma 
level of Apo C-III (Apo C-III < 10 mg/dL (blue dot) and Apo C-III > 10 mg/dL (red dot). 
 
 
The model with 3 LVs accounts for about the 80% of the information about class belonging and 
about the 30% of the information about the proteins.  
Table 14 reports the regression coefficients of the final model: a positive coefficient corresponds to 
proteins with a larger signal in patients with Apo C-III levels above 10 mg/dL and smaller signals in 
patients with Apo C-III levels below 10 mg/dL, while variables with a negative coefficient show an 
opposite behavior. The larger the absolute value of the regression coefficient, the larger the 
influence of the corresponding protein on the final model. The multivariate model identifies as 
discriminating a panel of proteins that on their whole increase and/or decrease in the two classes 
investigated: the regulations have to be identified as the contribution of all the 42 proteins on the 
final model, rather than observing single markers. In other words, the Backward Elimination 
variable selection (BE)-PLS-DA model identifies a correlation structure differentiating on its whole 
patients with low from those with high Apo C-III levels.  
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42 variables were significant for the two groups of CAD patients, in the Table 14 are reported the 
proteins correlated with patients with Apo C-III < 10mg/dL (blue) and with patients with Apo C-III 
> 10 mg/dL (red). 
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Table 14. Regression coefficients of the proteins included in the final BE-PLS-DA model containing 3 LVs. 
 
 
 PROTEIN NAMES COEFF. 
IGHG4_HUMAN Ig gamma-4 chain C region -0.0088 
PPC1A_HUMAN Phospholipid phosphatase 4 -0.0107 
IGHG3_HUMAN Ig gamma-3 chain C region (HDC) (Heavy chain disease protein) -0.0109 
LV104_HUMAN Immunoglobulin lambda variable 1-51 -0.0112 
LAC2_HUMAN Ig lambda-2 chain C regions -0.0161 
PON1_HUMAN Serum paraoxonase/arylesterase 1 -0.0260 
NRX3A_HUMAN Neurexin-3 (Neurexin III-alpha) (Neurexin-3-alpha) -0.0292 
SMAG2_HUMAN Protein Smaug homolog 2 -0.0351 
SLAI2_HUMAN SLAIN motif-containing protein 2 -0.0397 
GELS_HUMAN Gelsolin (AGEL) (Actin-depolymerizing factor) -0.0403 
HBB_HUMAN Hemoglobin subunit beta (Beta-globin) -0.0407 
A1BG_HUMAN Alpha-1B-glycoprotein (Alpha-1-B glycoprotein) -0.0450 
HBA_HUMAN Hemoglobin subunit alpha (Alpha-globin) -0.0488 
CO4A_HUMAN Complement C4-A (Acidic complement C4) -0.0507 
CO9_HUMAN Complement component C9 -0.0523 
KV103_HUMAN Immunoglobulin kappa variable 1D-33 -0.0537 
NSUN3_HUMAN Putative methyltransferase NSUN3 -0.0550 
KV106_HUMAN Immunoglobulin kappa variable 1-5 -0.0643 
KV306_HUMAN Immunoglobulin kappa variable 3-15 -0.0679 
KV309_HUMAN Immunoglobulin kappa variable 3-11 -0.0686 
A1AT_HUMAN Alpha-1-antitrypsin (Alpha-1 protease inhibitor) -0.0694 
SAA1_HUMAN Serum amyloid A-1 protein -0.0699 
AACT_HUMAN Alpha-1-antichymotrypsin (ACT) -0.0710 
HV305_HUMAN Immunoglobulin heavy variable 3-13 -0.0734 
PIEZ2_HUMAN Piezo-type mechanosensitive ion channel component 2 -0.0874 
TTHY_HUMAN Transthyretin (ATTR) (Prealbumin) (TBPA) 0.0140 
IGHA1_HUMAN Ig alpha-1 chain C region 0.0217 
FCN3_HUMAN Ficolin-3 (Collagen/fibrinogen domain-containing lectin 3 p35) 0.0219 
ITIH1_HUMAN Inter-alpha-trypsin inhibitor heavy chain H1 0.0287 
LBP_HUMAN Lipopolysaccharide-binding protein (LBP) 0.0338 
LV105_HUMAN Immunoglobulin lambda variable 1-40 0.0404 
GRD2I_HUMAN Delphilin (Glutamate receptor) 0.0415 
C1QC_HUMAN Complement C1q subcomponent subunit C 0.0521 
LAC7_HUMAN Ig lambda-7 chain C region 0.0534 
FHR1_HUMAN Complement factor H-related protein 1 0.0609 
CPN2_HUMAN Carboxypeptidase N subunit 2 0.0704 
APOC2_HUMAN Apolipoprotein C-II (Apo-CII)  0.0722 
RET4_HUMAN Retinol-binding protein 4 (Plasma retinol-binding protein) 0.0739 
AMBP_HUMAN Protein AMBP (Alpha-1 microglycoprotein) 0.0847 
APOH_HUMAN Beta-2-glycoprotein 1  (Anticardiolipin cofactor) 0.0976 
APOE_HUMAN Apolipoprotein E (Apo-E) 0.1001 
APOC3_HUMAN Apolipoprotein C-III (Apo-CIII) 0.1266 
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Table 15 reports the classification performances of the PLS-DA model with the backward 
elimination variable selection (BE-PLS-DA) applied to all the proteins and of the PLS-DA model 
calculated including all the 21 proteins resulted as statistically significant by the monovariate 
approach. 
 
 
Table 15. Classification performances of of the PLS-DA model with the BE-PLS-DA calculated including all the 21 
proteins resulted as statistically significant by the monovariate approach. Cross-validation results are presented for 51 
patients and 5 cancellation groups: in both cases all the replications of the same sample were excluded at a time.  
 BE-PLS-DA (42 variables) PLS-DA (21 variables identified by 
monovariate statistics) 
 Fitting CV (51 canc. 
groups) 
CV (5 canc. 
groups) 
Fitting CV (51 canc. 
groups) 
CV (5 canc. 
groups) 
Accuracy% 96.79 93.59 83.33 80.77 75.64 72.44 
NER% 97.47 94.21 85.38 82.99 78.58 74.56 
Precision 
class “low Apo C-III” 
91.94 87.30 70.67 67.53 61.45 58.75 
Precision 
class “high Apo C-III” 
100 97.95 95.06 93.67 91.78 86.84 
Sensitivity 
class “low Apo C-III” 
100 96.49 92.98 91.23 89.47 82.46 
Sensitivity 
class “high Apo C-III” 
94.95 91.92 77.78 74.75 67.68 66.67 
Specificity 
class “low Apo C-III” 
94.95 91.92 77.78 74.75 67.68 66.67 
Specificity 
class “high Apo C-III” 
100 96.49 92.98 91.23 89.47 82.46 
 
 
The results show that the panel of proteins identified by the multivariate strategy shows a better 
classification ability with respect to the model built including exclusively the markers identified by 
the monovariate approach. The results show good classification performances with quite good 
accuracy levels.  
The 42 significant variables obtained from the multivariate approach were then used to 
described/characterize the two CAD groups, to identify pathways and biological functions linked to 
“Apo C-III CAD state”. The STRING analysis, in Figure 20, of the proteins from the “high Apo C-
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III patients” shows the clear connection with the triglyceride catabolic process, the lipid binding and 
the lipid transport (Figure 20). 
 
 
 
Figure 20. STRING analysis of the proteins from the “high Apo C-III patients”(A) and “low Apo C-III patients”(B) 
group respectively. 
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4.6. Plasma Lipidomic analysis of patients stratified according to Apolipoprotein C-III 
Apolipoprotein E and Triglycerides 
Gas-Chromatography analysis versus Liquid Chromatography-Mass Spectrometry 
We analyzed a set of 39 plasma samples obtained from CAD and CAD free patients stratified 
according to Apo C-III, Apo E and TG levels in order to evaluate their lipids profiles get insights 
into the contribution of the different molecules. The general characteristic of the patients are shown 
in Table 16. We assessed FA by gas chromatography analysis and lipids by LC-MS. Briefly 
patients were subdivided into 6 groups: group 1 characterized by low levels of TG Apo E and Apo 
C-III, group 2 characterized by low levels of TG and Apo E and high levels of Apo C-III, group 3 
characterized by low levels of TG and Apo C-III and high levels of Apo E, group 4 characterized by 
low levels of TG and high levels of Apo E and Apo C-III, group 5 characterized by high levels of 
TG and low levels of Apo E and Apo C-III, group 6 characterized by high levels of TG, Apo E and 
Apo C-III. The six groups are illustrated in Table 17.  
The gas-chromatography (GC) analysis showed the presence of different classes of free fatty acids 
from 14 to 24 atoms of carbon in the plasma of analyzed subjects. The most abundant FAs were 
palmitic acid (C:16) and stearic acid (C:18). Observed as a whole, all the data gave by GC approach 
didn’t show a peculiar distribution for a possible classification, all of them presented similar 
profiles. On the other hand, the LC MS analysis was able to give separation profiles as illustrated in 
Figure 21, where molecules are separated according to the number of carbon chains and polarity.  
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Table 16. Clinical and laboratory characteristics of the cohort of CAD and CAD free patients. 
 Patients 
Age (years) 65.59±7.91 
Male sex (%) 48.7% 
CAD 46.2% 
Myocardial infarction history (%) 17.9% 
Smoking history (%) 35.9% 
Hypertension (%) 56.4% 
Diabetes (%) 12.8% 
Total cholesterol (mM/L) 5.3±1.21 
LDL cholesterol (mM/L) 3.3±0.95 
HDL cholesterol (mM/L) 1.44± 
Triglyceride (mM/L) 1.4±0.75 
Apolipoprotein A (g/L) 1.32±0.34 
Apolipoprotein B (g/L) 1.05±0.28 
Apolipoprotein E (g/L) 0.043±0.014 
Apolipoprotein C-III (mg/dl) 10.68±3.62 
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Table 17. Group of survey for lipidomic analysis 
 
Group 1 
↓TG-↓Apo C-III-
↓Apo E 
(n=5) 
Group 2 
↓TG-↑Apo C-III-
↓Apo E 
(n=4) 
Group 3 
↓TG-↓Apo C-III-
↑Apo E 
(n=5) 
Group 4 
↓TG-↑Apo C-III-
↑Apo E 
(n=5) 
Group 5 
↑TG-↓Apo C-III-
↓Apo E 
(n=5) 
Group 6 
↑TG-↑Apo C-III-
↑Apo E 
(n=5) 
P* 
Apo C-III 
(mg/dL) 
7.26±0.55 13.88±1.77 7.89±1.42 13.59±2.10 7.45±1.36 14.94±1.68 <0.001 
Apo E 
(g/L) 
0.029±0.003 0.030±0.005 0.046±0.002 0.059±0.008 0.034±0.002 0.058±0.009 <0.001 
TG 
(mmol/L) 
1.01±0.11 0.94±0.16 0.90±0.25 0.93±0.09 2.45±0.27 2.68±0.34 <0.001 
Age 
(years) 
68.8±3.8 69.3±2.9 62.8±3.6 66.6±7.2 57.0±4.4 63.8±5.5 0.013 
Males 
(n) 
3/5 0/4 3/5 2/5 4/5 3/5 NS 
CAD 
(n) 
3/5 3/4 1/5 3/5 5/5 3/5 NS 
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Figure 21. Chromatogram representative of the RPLC-ESI -MS analysis performed on plasma samples. 
 
 
A total of 254 lipid species were identified 34 Cholesteryl Esters (CE) and Cholesteryl Esters 
oxidized (CE-oxidized); 5 Ceramides; 9 Diacylglycerol (Gangabadage, Zdunek et al.); 9 
Lysophosphatidylcholines (Lyso-PC); 64 Phosphatidylcholines (PC); 9 Phosphatidylethanolamine 
(PE) 1 Lysophosphatidylethanolamine (PE); 9 Phosphatidylinositol (PI); 35 
sphingosylphosphorylcholine (SM); 79 triacylglycerol (TAG). 
The principal component analysis (PCA), an analysis unsupervised of the data (Figure 22) showed 
a subdivision of the population in 2 groups according to the Apo E levels (high Apo E levels in red, 
low Apo E in green). More precisely, in the red group were included most of the samples belonging 
to group 3, 4 and 6 (see Table 17) characterized by high levels of Apo E, while in the green group 
were included most of the sampler with low Apo E levels, i.e. groups 1, 2, and 5. The data were, 
analyzed by mean of scaling method of Pareto, which allows to reduce the influence of the most 
intense peaks and emphasizes the less intense metabolites still having a biological value. 
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Figure 22. Principal component analysis on the LC-MS data– Pareto Scaling – log transformed. PC1 explains 42% of 
the total information, instead the second component PC2 explains the 13% of total information. 
 
 
Then the Partial Least Squares- Discriminant Analysis (PLS-DA), a supervised method, was 
performed to give a validated model through permutation test (200 permutations) changing the 
samples order, considering statistically significant only model with a Q2> 0.5. According to this 
condition only two of all the models resulted statistically significant, the subdivision in two and 
three groups (Table 18). 
On these models we performed Orthogonal Partial Least Squares- Discriminant Analysis (OPLS-
DA) in order to identify the metabolites which contribute to the classes separation whit a cut off of 
p(corr)≥0.75. In this way it is possible to select the metabolite which will pass the t-test at 99%. 
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Table 18. Partial least square – discriminant analysis (PLS-DA) 
PLS-DA Model Q2 
Subdivision in 6 groups 0.0864 
Subdivision in 2 groups by PC1 0.944 
Subdivision in 3 groups byPC2 0.738 
Group 1 (↓TG-↓ApoC-III-↓ApoE) vs all -0.0202 
Group 2 (↓TG-↑ApoC-III-↓ApoE) vs all 0.291 
Group 3 (↓TG-↓ApoC-III-↑ApoE) vs all 0.432 
Group 4 (↓TG-↑ApoC-III-↑ApoE) vs all 0.291 
Group 5 (↑TG-↓ApoC-III-↓ApoE) vs all -0.0385 
Group 6 (↑TG-↑ApoC-III-↑ApoE) vs all 0.406 
 
 
 
The S-plot in Figure 23 shows the OPLS-DA on two groups (Q2=0.944-see Table 18). In red we 
can observed the metabolites associated to the groups with high levels of Apo E, instead in green 
we observe the metabolites associated to the groups with low levels of Apo E. All the metabolites 
have a p(corr)≥0.75 and are summarized in Tables 19 and 20. 
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Figure 23. S-plot shows the OPLS-DA on two groups (Q2=0.944) subdivided according to Apo E plasma levels. In the 
red are shown the metabolites that characterize the groups with high levels of Apo E. In the green circle are illustrated 
the metabolites that characterize groups with low levels of Apo E. Metabolites were selected according to p(corr)>0.75 
 
 
The OPLS-DA analysis of the patients with high levels of Apo E underlined the presence of 34 lipid 
species belonging to the family of PC, Lyso PC, TAG and CE (Table 19). In particular what is 
worth of interest is the presence of di-oxidized CE. In the group characterized by low levels of Apo 
E, instead, 48 lipid species were found, belonging, in particular, to the family of PC and TAG. None 
CE oxidized were observed (Table 20). 
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Table 19. Metabolites in samples with high Apo E levels (p corr)>0.75) 
m/z RT class ID 
756.674 4.33621 PC PC 34:2-OH -[M+H-18]+ 
774.571 4.92215 PC PC 34:2-OH (16:0/18:2-OH) 
790.569 3.31241 PC PC 34:2-OOH (16:0/18:2-OOH) 
772.664 5.17473 PC PC 34:3-OH (16:0/18:3-OH) 
772.654 5.5346 PC PC 34:3-OH (16:0/18:3-OH) 
802.546 7.36171 PC PC 36:2-OH (18:0/18:2-OH) 
800.604 7.77743 PC PC 36:3-OH (18:0/18:3-OH) 
800.553 8.23455 PC PC 36:3-OH (18:0/18:3-OH) 
780.616 4.05788 PC PC 36:4-OH (18:2/18:2-OH) 
496.383 1.48833 LYSO PC LYSO PC 16:0 
524.35 2.05214 LYSO PC LYSO PC 18:0 
480.419 1.69146 LYSO PC LYSO P-PC 16:1 
508.47 1.97039 LYSO PC LYSO P-PC 18:1 
510.49 2.59712 LYSO PC LYSO P-PC 18:0 
341.359 2.04925 LYSO PE LYSO PE 18:0 
867.749 34.6308 TAG TAG 50:3-OH (14:0/18:1/18:2-OH) - Na ADDUCT 
923.793 41.3612 TAG TAG 54:3 -OH (18:0/18:1/18:2-OH) - Na ADDUCT 
923.786 41.934 TAG TAG 54:3 -OH (18:0/18:1/18:2-OH) - Na ADDUCT 
895.705 37.8534 TAG TAG 52:3-OH - Na ADDUCT 
895.756 38.3996 TAG TAG 52:3-OH - Na ADDUCT 
645.562 48.8724 CE CE 16:1 - Na ADDUCT 
703.655 26.7012 CE CE 18:2 DIOXIDIZED - Na ADDUCT 
703.643 27.0215 CE CE 18:2 DIOXIDIZED - Na ADDUCT 
703.652 28.8351 CE CE 18:2 DIOXIDIZED - Na ADDUCT 
687.533 35.3774 CE CE 18:2-OH - Na ADDUCT 
687.629 32.3605 CE CE 18:2-OH - Na ADDUCT 
687.638 33.3578 CE CE 18:2-OH - Na ADDUCT 
701.658 29.3099 CE CE 18:3 -DIOXIDIZED - Na ADDUCT 
701.646 31.8689 CE CE 18:3 -DIOXIDIZED - Na ADDUCT 
685.543 35.4172 CE CE 18:3-OH - Na ADDUCT 
727.613 21.8935 CE CE 20:4 DIOXIDIZED - Na ADDUCT 
727.586 22.616 CE CE 20:4 DIOXIDIZED - Na ADDUCT 
727.544 23.4461 CE CE 20:4 DIOXIDIZED - Na ADDUCT 
727.636 25.2206 CE CE 20:4 DIOXIDIZED - Na ADDUCT 
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Table 20. Metabolites in sample with low Apo E levels (p(corr)>0.75) 
m/z RT Class ID 
756.607 10.31 PC PC 34:3 
756.621 11.1355 PC PC 34:3 
768.529 11.0706 PC PC 35:4 
784.611 14.7277 PC PC 36:3 
782.545 12.3839 PC PC 36:4 
780.545 10.116 PC PC 36:5 
780.527 10.8735 PC PC 36:5 
812.55 18.4739 PC PC 38:3 
812.596 19.3135 PC PC 38:3 
810.513 16.4369 PC PC 38:4 
810.548 17.3714 PC PC 38:4 
810.475 15.6519 PC PC 38:4 
808.46 13.8714 PC PC 38:5 
808.45 14.9887 PC PC 38:5 
806.439 12.0739 PC PC 38:6 
806.459 12.6321 PC PC 38:6 
836.586 18.4013 PC PC 40:5 
834.625 16.9473 PC PC 40:6 
768.572 15.6778 PC P-PC 36:4 (O:16:O/20:4) 
766.612 14.8734 PC P-PC 36:5 (O:16:1/20:4) 
796.627 20.3791 PC P-PC 38:4 (O-18:0/20:4) 
794.604 16.5194 PC P-PC 38:5 (O-18:1/20:4) 
629.646 12.3116 PI PI 38:3 
627.633 10.887 PI PI 38:4 
627.607 14.3786 PI PI 38:4 
731.594 15.673 SM SM 36:1 
873.78 44.5087 TAG TAG 52:6 - Na ADDUCT 
875.819 46.2899 TAG TAG 52:5 (16:1/18:2/18:2) - Na ADDUCT 
899.687 45.7328 TAG TAG 54:7 (18:2/18:2/18:3) - Na ADDUCT 
901.723 47.3067 TAG TAG 54:6 (18:2/18:2/18:2) - Na ADDUCT 
901.712 48.9914 TAG TAG 54:6 - Na ADDUCT 
903.712 52.7673 TAG TAG 54:5 - Na ADDUCT 
903.731 50.762 TAG TAG 54:5 (18:1/18:2/18:2) - Na ADDUCT 
925.71 46.7861 TAG TAG 56:8 - Na ADDUCT 
925.718 47.8327 TAG TAG 56:8 - Na ADDUCT 
927.641 49.6071 TAG TAG 56:7 - Na ADDUCT 
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927.644 51.3708 TAG TAG 56:7 - Na ADDUCT 
929.66 53.5527 TAG TAG 56:6 - Na ADDUCT 
929.656 54.4679 TAG TAG 56:6 - Na ADDUCT 
931.724 56.9054 TAG TAG 56:5 - Na ADDUCT 
931.714 58.0723 TAG TAG 56:5 - Na ADDUCT 
931.722 59.576 TAG TAG 56:5 (18:0/18:1/20:4) - Na ADDUCT 
669.645 46.5392 CE CE 18:3 - Na ADDUCT 
693.633 45.3807 CE CE 20:5 - Na ADDUCT 
695.623 48.6954 CE CE 20:4 - Na ADDUCT 
697.657 51.7641 CE CE 20:3 - Na ADDUCT 
719.626 47.1568 CE CE 22:6 -Na ADDUCT 
711.554 33.5169 CE CE 20:4-OH - Na ADDUCT 
 
 
According to PLS-DA on the subdivision in three groups (Q2=0.738 Table 18) PLS-DA (Figure 
24) confirms the data observed for the analysis for the subdivision in 2 groups but, underlines also 
the presence of a third category of population (orange) with high levels of Apo E and low levels of 
Apo C-III (group 3 Table 17). 
 
 
Figure 24. PLS-DA on three groups: Q2: 0.738 
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The OPLS-DA confirmed the data obtained with PLS-DA and the presence of three groups 
classification but for the third group (orange) none of the metabolites already observed for the other 
groups were found. This third group didn’t present any possible marker ( see Figure 25). 
 
 
 
 
Figure 25. OPLS-DA on three groups. The dots indicate the metabolites while the triangles indicate the sample. All the 
metabolites observed near the sample are the metabolites that characterized the group. 
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5. DISCUSSION  
5.1.Distribution of glycoforms of Apolipoprotein C-III in coronary patients  
Apo C-III is present mainly in 3 isoforms termed Apo C-III0, Apo C-III1, and Apo C-III2, 
depending on the number of sialic acid molecules (0 to 2) at the oligosaccharide portions of the 
protein (Nicolardi, van der Burgt et al. 2013). It has been estimated that each glycoform may 
physiologically contribute, respectively, to approximately 10%(Apo C-III0), 55% (Apo C-III1), and 
35% (Apo C-III2) of the total circulating Apo C-III levels (Nicolardi, van der Burgt et al. 2013). We 
firstly analyzed Apo CIII glycoforms by IEF. Isofocusing is a simple and rapid technique that 
allows semi-quantitative determination of Apo C-III glycoforms. We analyzed 4 groups of CAD 
patients stratified according to Apo C-III and PUFA levels.  
By the IEF approach for the quantification of the three Apo C-III glycoforms in the four observed 
groups we found that despite the high levels of total Apo C-III in group 3 (Table 4 ), a proportion 
between glycoforms 1 and 2 is maintained probably due to the known positive effect of PUFA. On 
the contrary, patients of group 4, having low PUFA plasma levels, presented an alteration of the 
relative proportion between the glycoforms 1 and 2, being Apo C-III1 more abundant. We observed 
that the group 3, selected for high Apo C-III levels, showed TG mean concentrations lower than 
expected. The finding suggests that this group might represent a peculiar subset in which the 
association high Apo C-III-high TG is missing. This apparent anomaly deserves further in-depth 
study to assess the incidence of cardiovascular events and the overall survival in this specific patient 
subset. 
 
 
5.2. Deregulated plasmatic proteins in CAD patients with different Apo C-III levels 
On the basis of the role of the Apo C-III not only in the lipoprotein metabolism but also in 
inflammatory phenomena and thrombotic events, worth of interest is to observe how the total 
plasma Apo C-III concentration may affects the expression of the proteins involved in such 
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different pathway. Then, exploiting previous comparative analysis results, on the same population 
of IEF analysis, we decided to select five proteins ( Serum Amyloid Protein, Fibrinogen β, 
Fibrinogen γ, Fibrinogen γ’ and Complement C3) differentially expressed according to Apo C-III 
concentration and to validate the results by western blotting.  
Interestingly, we found that patients with high Apo C-III have a lower plasmatic level of serum 
amyloid P component. This protein is a member of pentraxins family, that promotes the cholesterol 
efflux from cells (Song, Cai et al. 2010). It binds the oxidized LDLs, preventing lipids storage in 
macrophages and their conversion into foam cells that would bring to atherosclerotic damage 
formation (Stewart, Tseng et al. 2005). The data allow to hypothesize that patients with high Apo 
C-III could be therefore more prone to the formation of atherosclerotic plaques also as a 
consequence of reduced plasma levels of serum amyloid P component. Further evidence is however 
necessary to definitively confirm this hypothesis.  
According to a previous study, Apo C-III is involved not only in atherosclerotic plaques formation, 
but also in the coagulation pathway, since there is an independent association between Apo C-III 
levels and thrombin generation (Olivieri, Martinelli et al. 2010). So it is worth noting that we 
observed in patients with high Apo C-III a modulation of different fibrinogen chains. In particular, 
we found decreased levels of fibrinogen β and increased levels of fibrinogen γ in patients with high 
Apo C-III. Fibrinogen γ prime (γ’) arises from a splice variant of the γ-chain messenger RNA 
resulting from an alternative polyadenylation signal in intron 9 (Chung and Davie 1984, Fornace, 
Cummings et al. 1984). The alternative polyadenylation leads to the translation of a unique 20-
amino-acid C-terminal extension encoded by intron 9, which substitutes the 4 amino acids of exon 
10 (Fornace, Cummings et al. 1984, Drouet, Paolucci et al. 1999, Mannila, Lovely et al. 2007). The 
association with different thrombotic diseases has been ascribed in part to the effects of γ’ on clot 
structure, on thrombin activity and fibrinolysis (Uitte de Willige, Standeven et al. 2009). Several 
studies show that fibrinogen γ’ levels increased in CAD patients (Lovely, Falls et al. 2002, Lovely, 
Kazmierczak et al. 2010). Fibrinogen γ’ is associated with an opposite trend with both venous (Uitte 
77 
de Willige, de Visser et al. 2005, Lovely, Boshkov et al. 2007, Lovely, Kazmierczak et al. 2010) 
and arterial thrombosis (Drouet, Paolucci et al. 1999, Lovely, Falls et al. 2002, Mannila, Lovely et 
al. 2007, Cheung, Uitte de Willige et al. 2008, van den Herik, Cheung et al. 2011). This association 
with different thrombotic disorders has been ascribed in part to the effects of fibrinogen γ’ on clot 
structure, crosslinking by factor XIIIa, thrombin activity, or fibrinolysis (Uitte de Willige, 
Standeven et al. 2009). In particular it was observed how this protein has thrombogenic effects in 
arterial site (Uitte de Willige, Standeven et al. 2009) and anti-thrombogenic effect in venous site 
(Uitte de Willige, de Visser et al. 2005, Lovely, Boshkov et al. 2007).Since it could be supposed 
that these latter function could be associated with Apo C-III levels, we performed 1D and 2D 
immunoblottin analyses of fibrinogen γ‘ chain (Figure. 6 and Figure.7). The data confirmed the 
comparative analysis results. Briefly we observe an down-regulated Fibrinogen β in groups with 
high levels of Apo C-III compared to groups with low levels of Apo C-III and in groups with high 
Apo C-III levels an up-regulation of Fibrinogen β in profile B (low PUFA levels). An opposite 
trend, instead was observed for the Fibrinogen γ and γ’ an up-regulation in groups with high levels 
of Apo C-III compared with low levels of Apo C-III, with also an up- regulation in groups with low 
levels of Apo C-III profile A (high PUFA). 
Finally atherosclerosis is an inflammatory disease and several studies suggest that the complement 
system, being one of the main components of innate immunity, is involved in its pathogenesis, 
although its role has not yet been fully elucidated. Growing evidences indicate that complement 
activation occurs within atherosclerotic plaques, playing a dual effect: it has a protective function 
removing apoptotic cells and cell debris from atheroma, and it also induces pro-inflammatory 
events leading to the destabilization of the plaque (Speidl, Kastl et al. 2011). We reported the 
modulation of several components of complement but in particular, the increase of complement C3 
levels suggested that this component is not consumed. The 2D western blotting analysis confirmed 
the complement C3 trend (Figure 7), underlining an upregulation of this protein in patients with 
low levels of Apo C-III profile A (high PUFA) versus patients with profile B (low PUFA). 
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5.3. Apolipoprotein C-III quantification by Shotgun-Top down MS analysis 
We moved to a more powerful technology for the analysis of Apo C-III isoforms, being able to 
quantify Apo C-III0, 1 and 2, in 51 stable CAD patients, carefully selected. 
Apo C-III- and TG- rich particles not only may contain variable amounts of other apolipoproteins 
(such as Apo B and Apo E) but also may differ in their relative proportions of sialylated isoforms of 
Apo C-III. A substantially unresolved question concerns the fact whether – in case of pathological 
increase of Apo C-III - all these isoforms change in parallel, or asymmetric variations for some of 
them may be recognized. As Apo C-III sialylation appears to be under metabolic control (Yassine, 
Trenchevska et al. 2015), this latter possibility may associate with metabolic and cardiovascular 
disorders and therefore be particularly important in patients with high “residual CV risk” such as 
CAD patients treated with statins but still presenting elevated Apo C-III concentrations.  
This study aimed at answering this question through a rather original approach, i.e. by examining 
two subgroups of CAD patients, all treated with statins but showing a fully divergent concentration 
(very low vs very high) of total circulating Apo C-III.  
By this approach, it was possible not only to compare subjects at very different risk in the setting of 
the secondary cardiovascular prevention, but also to study the proportional expression of the various 
isoforms through the entire range of concentrations of Apo C-III. Under this respect, the most 
important results are graphically summarized in Figure 8, where the relative proportions of any 
single isoform are plotted against the total plasma concentration of Apo C-III. The only glycoform 
that strictly reflects the trend of the total apolipoprotein concentrations was the monosialylated 
form, Apo C-III1. In contrast, fully or non- sialylated (Apo C-III2 and Apo C-III0, respectively) did 
not correlated at all or even presented a negative correlation with the total Apo C-III (Figure 8).  
The finding of a “neutral” proportion and a quite stable ratio of di-sialylated isoform Apo C-III2 to 
total Apo C-III is consistent with the results recently presented by Yassine and coll. (Yassine, 
Trenchevska et al. 2015) but not by others (Koska, Yassine et al. 2016); of note, both in our study 
and in the Yassine’s one, a MS methodology was used, while this was not the case for previous 
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reports that instead adopted an iso-electrofocusing (IEF) based approach for isoforms evaluation 
(Wopereis, Grunewald et al. 2003, Wada, Kadoya et al. 2012).  
It is therefore plausible that these results are largely dependent on the methodology employed; as 
MS is generally considered more precise and reliable than IEF, any comparison among reports 
using methodologies other than MS is likely meaningless.  
More surprising and even counterintuitive was the distinct association between relative amounts of 
Apo C-III0 (non-sialylated) isoform and total Apo C-III, that resulted to be related in a negative 
way. In other words, CAD patients presenting lower concentrations of total Apo C-III were also the 
individuals with higher proportion of non-sialylated apolipoprotein, thus suggesting to some extent 
a protective role for this isoform. 
In principle, it is possible to speculate that low levels of total Apo C-III match low levels of its 
isoforms. The observed paradoxical behavior may be explained by metabolic or pharmacological 
reasons. Considering that all patients were taking statins, the result could be related to a different 
pharmacological sensitivity for statins of a subgroup of individuals. Subjects receiving the maximal 
benefit in terms of reduction of total Apo C-III by statin therapy can have a decrease in their relative 
amount of sialylated isoforms and, in turn, a proportional apparent increase in Apo C-III0 content. 
On the contrary, patients with persistently elevated total Apo C-III, i.e. in a “statin-resistant” 
condition, seemed to be characterized by an increase of monosialylated isoforms. This may be in 
agreement with a possible inhibitory role of the statins on the apolipoprotein sialylation process. 
Thus, the relation between pharmacological effects of these drugs and sialylation may open new 
perspectives that deserve further investigation. 
The second question addressed in the present work concerns the relationship between Apo C-III 
glycoforms and other lipids and lipoproteins, in particular with the “harmful” Apolipoprotein B and 
the “protective” Apolipoprotein E.  
Our results suggest that Apo C-III glycoforms vary in their association with plasma lipids and 
apolipoproteins and therefore - in turn – with the cardiovascular risk traditionally associated with 
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their levels. Thus, a measure of total Apo C-III may not strictly reflect the overall risk represented 
by the single isoform. In a comparable way to the concentration of total Apo C-III, the 
monosialylated isoform resulted to be statistically correlated with a less favorable lipid profile, 
including an increase of plasma total and LDL cholesterol, TG, Apo B and Apo E. As a 
consequence, a relatively elevated amount of this isoform seemed to characterize the same 
“harmful” lipid situation that was observed when total Apo C-III is elevated. Many previous studies 
in fact showed not only that total Apo C-III concentrations are associated with circulating Apo B-
enriched lipoproteins carrying substantial amount of cholesterol and TG, but also that this 
represents a condition of elevated risk for CAD patients (Alaupovic, Mack et al. 1997, Lee, Campos 
et al. 2003, Mendivil, Rimm et al. 2011, Mendivil, Rimm et al. 2013).  
The relationship between Apo C-III glycoforms and Apo E has been poorly investigated. Particles 
rich in Apo C-III are also abundant in Apo E (Zheng, Khoo et al. 2007, Mendivil, Zheng et al. 2010, 
Zheng, Khoo et al. 2010). The opposing actions of Apo C-III and Apo E on subspecies of VLDL 
and LDL represent important factors modulating Apo B lipoprotein metabolism: it was indeed 
suggested that, in presence of Apo E, lipoproteins are cleared more rapidly from the circulation 
(Sacks 2015). We did not analyze the single species of lipoproteins, however, in light of the 
findings obtained (positive and negative correlation for Apo C-III1 and Apo C-III0, respectively; 
see Table 7) Apo C-III1/Apo C-III0 ratio may reflect the relative abundance of Apo E on these 
particles. Accordingly, for the same concentration of total Apo C-III, individuals with highest Apo 
C-III1/Apo CIII0 ratio should have more Apo E in their TG- rich lipoproteins. 
Furthermore the design of the study and the patients selection were planned to clarify how fatty 
acids, and more specifically PUFA, affect the glycoforms distribution. While total Apo C-III 
decreased with increasing PUFA (R=-0.530; P<0.001, Table 9), the pattern of distribution of the 
single isoforms did not change in presence of large variations of the dietary intake of total PUFA 
(i.e. including both ω3 and ω6 families). When the group of patients was separated by low or high 
PUFA intake, an association trend was present for Apo C-III0 and Apo C-III1 but this was limited 
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to the situation of “low risk” (low total apolipoprotein). The results were particularly clear for ω3 
PUFA that showed a null capability to interfere with the glycoforms (Table 9).  
A similar situation was also observed for total MUFA that correlated with total Apo C-III but not 
with its isoforms. Thus, these findings confirm the interaction between dietary FA intake and 
apolipoprotein production and metabolism but do not suggest relevant dietary influences on the Apo 
C-III glycosilation. The relative proportions of Apo C-III glycoforms are probably unaffected by 
changing the quality of FAs in the diet or by administering ω3 PUFA for therapeutic purposes. 
The data obtained provided information on the complex relation among Apo C-III glycoforms, 
lipids and lipoproteins defining the dynamics of the sialylation process through the entire range of 
concentrations of Apo C-III. Regardless of the cause (pharmacologically by statins and/or 
genetically induced), the findings obtained in presence of low levels of Apo C-III should be of 
general value in terms of pathophysiology. In the opposite case, the value of the present data is 
instead specifically of interest for CAD patients in the setting of secondary prevention, one of the 
most important challenge for future cardiovascular research. 
The work suffers from some limitations that need to be acknowledged. First, the sample size of 
patients is relatively limited so that possible statistical associations may result overlooked. The 
selection of patients with very low or very high concentrations of Apo C-III should however 
amplify the differences arising from such opposite conditions. 
In second instance, the individuals investigated were patients affected by CAD; therefore all 
conclusions have to be restricted to this specific condition. Similarly, it is necessary to take into 
consideration that all patients were treated with statins. Such treatment may have influenced some 
results; for example, the cholesterol-lowering effect of these drugs may have weakened the 
correlations with plasma lipids. Nevertheless, accurate information on the Apo C-III metabolism is 
probably valuable in the context of the secondary prevention of CAD patients presenting a “residual 
risk” in spite of the best available therapy.  
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5.4. LPL activity study and Apolipoprotein C-III glycoforms correlation analysis  
According to inhibitory effect of the Apo C-III on the lipoprotein lipase (Brown and Baginsky 
1972, Wang, McConathy et al. 1985, Yamamoto, Morita et al. 2003), worth of interest cold be 
observing how the three different Apo C-III glycoforms could affect this function. In 51 CAD 
patients, we measured LPL activity in order to observe possible correlations and/or modulation of 
the inhibitory action of the three different glycoforms. 
Our result on LPL activity suggest that the total Apo C-III concentration of the apolipoprotein is 
more important in modulating (with an inhibitory influence) LPL activity than the relative 
proportions of glycoforms. LPL activity decreased progressively by increasing total Apo C-III 
plasma levels and similar trends were observed for each of the three glycoforms (Figure14-15), 
thereby suggesting that if Apo C-III glycoforms could have different functional role such difference 
would be not related to the influence on LPL.  
 
5.5. Proteomics analysis by SWATH 
Different proteomic pathways are involved in CAD condition, this is the reason why a SWATH 
analysis (untargeted proteomics approach) for the characterization of proteomic profile of CAD 
patients could be useful to get new insights into the molecules playing major roles in this pathology. 
The monovariate analysis underlined the presence of 21 up and down regulated proteins associated 
with high levels of Apo C-III. In particular among these protein there were 7 up regulated and 4 
down regulated with a FC >1.5 (Table 13). By the Cytoscape analysis (Figure 17) of these 21 
proteins we could reveal the presence of four functional clusters linked to the complement 
activation, the low-density lipoprotein metabolism, the acute phase response and the intermediated 
filament based process.  
Among these four highlighted groups, the low-density lipoprotein cluster is the most prominent and 
the proteins included in it were all upregulated. A predominance of small, low-density lipoprotein 
(LDL) in plasma has been already accepted as an emerging cardiovascular risk factor (Rizzo and 
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Berneis 2006). Moreover several evidence supports a functional role for complement activation in 
the pathogenesis of cardiovascular disease through pleiotropic effects on endothelial and 
hematopoietic cell function and hemostasis. Prospective and case control studies have reported 
strong relationships between numerous complement components and cardiovascular outcomes. 
Moreover, in vitro studies and animal models support a functional effect of complement activation 
on cardiovascular diseases (Carter 2012). In this cluster both up and down regulated proteins were 
present. On the other hand proteins included in the acute phase response cluster were down-
regulated. The acute phase reaction is a systemic response, which usually follows a physiological 
condition that takes place in the beginning of an inflammatory process. Cardiovascular diseases are 
characterized by the elevation of several positive acute phase reactants but are also associated with 
the reduction of negative acute phase reactants, as evidenced by Ahmed at al. (Ahmed, Jadhav et al. 
2012). 
The network related to lipoproteins, already highlighted by Cytoscape, shows that APOC3 and 
APOC2 have a co-expression connection while APOC3 - APOE and APOC2 - APOE are 
characterized by an interaction linked to literature works. The strict coexistence on TRL of Apo C-
III and Apo C-II is well known, so that the finding is largely expected. Apolipoprotein E (Apo E) 
was initially described as a lipid transport protein and major ligand for LDL receptors with a role in 
cholesterol metabolism and cardiovascular disease. Apo E is often reported to modify the effects of 
environmental risk factors such as diet, smoking, or physical activity on cardiovascular outcomes 
(Mahley 2016). 
Another protein linked to the regulation of lipoprotein metabolism is Retinol binding protein 4 
(RBP4). RBP4 concentrations were weakly correlated with both total cholesterol and triglycerides. 
Several studies have confirmed the associations of circulating RBP4 with obesity, insulin resistance, 
type 2 diabetes and cardiovascular risk factors (Ingelsson, Sundstrom et al. 2009). 
Proteins related to the complement activation did not show any connections in STRING, but, 
among these, there is Vitronectin (VTN), an adhesive glycoprotein, that is involved in various 
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functions including complement activation, blood coagulation, binding to proteoglycans, and 
modification of the matrix. The levels of vitronectin in plasma increased in patients with coronary 
artery diseases, showing a positive correlation with the severity of the disease. Indeed, patients with 
high levels of Apo C-III have an up-regulation of this protein (Derer, Barnathan et al. 2009). 
Our data reflect these results. It is also known that vitronectin accumulates in atherosclerotic 
plaques by both diffusion from plasma and in situ synthesis (Dufourcq, Louis et al. 1998) and that 
extent of coronary artery disease correlates with its plasma levels (Ekmekci, Ekmekci et al. 2005). 
Other proteins as Complement C2, Complement C1q (C1QC) and immunoglobulin IGLL5 were 
found upregulated. During recent years complement mediated inflammation has been shown to be 
an important player in a variety of heart diseases. Evidence points to an association between the 
complement system and heart diseases. Thus, complement seems to be important in coronary heart 
disease as well as in heart failure, where several studies underscore the prognostic importance of 
complement activation (Lappegard, Garred et al. 2014). 
Serum amyloid A-1 (SAA1) protein and alpha-1-antitrypsin are acute phase proteins. In particular 
several studies show as high expression of SAA1 may contribute to atherosclerosis (Fyfe, 
Rothenberg et al. 1997, Schillinger, Exner et al. 2005) and an elevated SAA1 concentrations 
associated with an increased risk of cardiovascular disease events (Johnson, Kip et al. 2004). 
Regarding Alpha- 1-antitrypsin, one of the major serine proteinase inhibitor in human plasma, it 
inhibits overexpressed proteinases during inflammation (Kalsheker 1994). It is important to 
underline as some pathological conditions, where oxidative stress could play a major role, are 
characterized by an impairment of the tight regulation between proteases and their inhibitors (Banfi, 
Brioschi et al. 2008). A failure of alpha 1-antitrypsin levels may be associated with a worse clinical 
course (Gilutz, Siegel et al. 1983).  
By the multivariate analysis, we obtained 42 significant variables which characterized Apo C-III 
CAD state (Table 14). This analysis confirmed the monovariate results as it is shown in Figure 20.  
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In particular the complement system, which plays a central role in innate immunity and also 
regulates adaptive immunity, is significantly prominent both for patients with low and for patients 
with high Apo C-III. 
Low density lipoprotein are clearly significant for patients with high levels of Apo C-III as already 
confirmed by the fold change analysis: in fact this class of protein is up-regulated for patients with 
high level of Apo C-III. 
The multivariate analysis identified as significant one more lipoprotein, the apolipoprotein H (Apo 
H). Apo H is a single chain glycoprotein involved in clotting mechanisms and lipid pathways. 
Plasma concentrations of Apo H are strongly associated with the metabolic syndrome and 
cardiovascular disease in type 2 diabetic patients and could be considered as a clinical marker of 
cardiovascular risk. The increased Apo H concentration is commonly associated to its increased 
liver synthesis (Crook 2010). Lipopolysaccharide-binding protein (LPB) has been shown to bind to 
lipopolysaccharides, lipoproteins, and lipopeptides and is a soluble acute-phase protein. LPB is the 
first protein to encounter lipopolysaccharide and to deliver it to its cellular targets. Its presence 
might be a reliable biomarker that indicates activation of innate immune responses. Elevated levels 
of circulating LBP represent a strong and independent predictor of the presence of CAD in men 
(Lepper, Schumann et al. 2007). 
For what concern the acute phase response proteins, which are significant for patients with low Apo 
C-III, the multivariate analysis was able to identify the alpha-1 antichymotrypsin in addition to 
SAA1 and Alpha-1-antitrypsin,. The serine protease inhibitor alpha-1 antichymotrypsin (ACT) has 
been implicated in the pathology of a number of devastating human diseases including chronic 
obstructive pulmonary disease (COPD), Parkinson’s disease (PD), Alzheimer’s disease (AD), 
Stroke, Cystic Fibrosis, Cerebral Hemorrhage and Multiple System Atrophy. ACT is an acute phase 
protein and its gene expression is stimulated by the presence of cytokines. ACT acts as an inhibitor 
of several serine proteases is a typical acute phase protein, with the amount of circulating protein 
dramatically increasing in response to inflammation (Baker, Belbin et al. 2007). 
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It is very interesting to note that the multivariate analysis uncovered two new significant proteins 
related to the oxygen transport: Hemoglobin subunit alpha (HBA) and Hemoglobin subunit beta 
(HBB). Although HBA and HBB resulted not modulated from the monovariate analysis, patients 
with high level of Oxygen proteins are often linked to anemia, which is a risk factor for adverse 
cardiovascular disease outcomes. Anemia has been shown to be an independent cardiovascular risk 
factor and a negative predictor of survival in patients with congestive heart failure. Furthermore, a 
lower hemoglobin level is also a risk factor for worse outcome in patients with coronary artery 
disease after myocardial infarction and percutaneous coronary intervention. Recently, there has 
been considerable interest in the relation between hemoglobin levels and cardiac outcomes. 
The analysis of the plasma profiles of these stable CAD patients revealed the strong implication of 
lipoproteins (Apo C-II and Apo E), retinol-binding protein 4 and vitronectin. Surprisingly the alpha 
1-antitrypsin was down-regulated in patients with high Apo C-III: this modulation could explain the 
worsening of the clinical course of this group of patients. Although our findings need to be verified 
in larger groups, this proof of concept allowed to study the physiologically expression of plasma 
proteins through the entire range of concentrations of Apo C-III and to link them to secondary 
cardiovascular prevention in CAD patients. 
 
5.6. Lipidomics approach 
The lipidomic study of the CAD and CAD free patients stratified according to TG, Apo C-III and 
Apo E levels, could give new insights into the knowledge of the burden of parameters associated 
with CAD and how the lipid profile could be associated with the CAD pathological condition. 
The population was subdivided in six different groups with different distribution of the three 
selected parameters (Table 17) and was subjected to both Gas-chromatography(GC) and Liquid 
Chromatography-MS (LC-MS). 
The first analysis, by GC didn’t allows a subdivision and classification of the patients, being all the 
parameters similar. On the contrary the LC-MS analysis allowed a classification of the patients, on 
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the basis of all the lipids quantified, according to the Apo E levels. In particular the PCA analysis 
underlined a distribution of all the patients in two groups: high Apo E versus low Apo E according 
to PC1 (Figure 22) and in three groups according to PC2 (Figure 24). The following PLS-DA 
analysis (Table 18) confirmed the significance of the distribution of all the patient in two and three 
groups (Q2>0.5). Than the OPLS-DA analysis identified the metabolites that characterized the 
distribution of the patients in the two and three groups (Figure 23-25).  
Of note the group characterized by high levels of Apo E presented among all the metabolites 
Cholesteryl ester oxidized (CE-Ox) species which were absent in patients characterized by low 
levels of Apo E (Table 19-20). This finding is of particular relevance and deserve further 
investigation. Earlier studies estimated that 2% of the total CE is oxidized in human plaque (Suarna, 
Dean et al. 1995) and also by recent study employing mass spectrometry on atherosclerosis lesion it 
could be possible to observe the presence of CE-Ox in atherosclerosis lesion (Hutchins, Moore et al. 
2011). Even if preliminary, these results on the lipidomic profiles of CAD patients seem to point 
out an association of Apo E with an unfavorable lipid distribution. Further analysis are ongoing in 
order to disclose other correlations and potential effect of the different lipid species observed in the 
different groups. 
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6. CONCLUSIONS 
In conclusion our study suggest that: 
 The shotgun topdown MS approach is a more reliable method than IEF to quantify the three 
different Apo C-III glycoforms 
 The more abundant Apo C-III glycoforms is the monosialylated and it is associated with the 
highest TG levels, showing a positive correlations with all the lipoproteins and lipid profile 
associated with CAD. 
 The validation analysis confirmed that high levels of Apo C-III are associated with a pro-
atherogenic and pro-inflammatory proteomic profile 
 LPL activity analysis highlighted how the total Apo C-III plasma concentration is more 
important in modulating (with an inhibitory influence) LPL activity than the relative 
proportion of glycoforms. 
 The SWATH analysis revealed a set of proteins associated with a “high and low Apo C-III 
state” 
 Lipidomic approach illustrated a different point of view on the possible markers associated 
to the plasma levels of Apo C-III and Apo-E in CAD.  
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